Drugging the undruggable RAS: Mission Possible?

Nature Reviews Drug Discovery
13, 828-851
DOI: 10.1038/nrd4389

Citation Report

#	Article	IF	Citations
2	Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Scientific Reports, 2015, 5, 13347.	1.6	13
3	Overview of KRASâ€Driven Genetically Engineered Mouse Models of Nonâ€Small Cell Lung Cancer. Current Protocols in Pharmacology, 2015, 70, 14.35.1-14.35.16.	4.0	12
4	Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A. Journal of Hematology and Oncology, 2015, 8, 132.	6.9	20
6	Direct Modulation of Small GTPase Activity and Function. Angewandte Chemie - International Edition, 2015, 54, 13516-13537.	7.2	63
7	Selective Targeting of the KRAS Codonâ€...12 Mutation Sequence by Pyrroleâ€“Imidazole Polyamide secoâ€CBI Conjugates. Chemistry - A European Journal, 2015, 21, 14996-15003.	1.7	17
8	Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins: Structure, Function and Bioinformatics, 2015, 83, 898-909.	1.5	58
9	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget, 2015, 6, 20785-20800.	0.8	112
10	Oncogenic RAS Mutants Confer Resistance of RMS13 Rhabdomyosarcoma Cells to Oxidative Stress-Induced Ferroptotic Cell Death. Frontiers in Oncology, 2015, 5, 131.	1.3	71
11	pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins. PLoS Computational Biology, 2015, 11, e1004469.	1.5	31
12	Oncogene-dependent survival of highly transformed cancer cells under conditions of extreme centrifugal force â€“ implications for studies on extracellular vesicles. Cellular and Molecular Biology Letters, 2015, 20, 117-29.	2.7	2
13	GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site. Journal of Biological Chemistry, 2015, 290, 28887-28900.	1.6	73
14	Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 335-344.	1.0	17
15	Reversible Effects of Peptide Concentration and Lipid Composition on H-Ras Lipid Anchor Clustering. Biophysical Journal, 2015, 109, 2467-2470.	0.2	23
16	The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular and Cellular Oncology, 2015, 2, e1054549.	0.3	301
17	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	2.0	200
18	Addressing the Right Targets in Oncology. Journal of Biomolecular Screening, 2015, 20, 305-317.	2.6	14
19	Seeing is believing: Ras dimers observed in live cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9793-9794.	3.3	14
20	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Molecular Cancer Research, 2015, 13, 1325-1335.	1.5	503

#	Article	IF	Citations
21	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Seminars in Thoracic and Cardiovascular Surgery, 2015, 27, 36-48.	0.4	8
22	Emerging EPO and EPO receptor regulators and signal transducers. Blood, 2015, 125, 3536-3541.	0.6	129
23	Membrane lipid therapy: Modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. Progress in Lipid Research, 2015, 59, 38-53.	5.3	181
24	KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. Scientific Reports, 2015, 5, 9696.	1.6	74
25	Ras moves to stay in place. Trends in Cell Biology, 2015, 25, 190-197.	3.6	88
26	Metabolic Dependencies in RAS-Driven Cancers. Clinical Cancer Research, 2015, 21, 1828-1834.	3.2	192
27	KRAS as a Therapeutic Target. Clinical Cancer Research, 2015, 21, 1797-1801.	3.2	262
28	Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. Clinical Cancer Research, 2015, 21, 1810-1818.	3.2	73
29	RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?. Clinical Cancer Research, 2015, 21, 1802-1809.	3.2	146
30	Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?. Clinical Cancer Research, 2015, 21, 1819-1827.	3.2	323
31	Targeting RAS -mutant Cancers: Is ERK the Key?. Trends in Cancer, 2015, 1, 183-198.	3.8	104
32	Computational allosteric ligand binding site identification on Ras proteins. Acta Biochimica Et Biophysica Sinica, 2016, 48, 3-10.	0.9	24
33	The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-ÎºB and RalB signaling pathways. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 1375-1384.	0.9	28
34	Thyroid C-Cell Biology and Oncogenic Transformation. Recent Results in Cancer Research, 2015, 204, 1-39.	1.8	39
35	The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?. Acta Biochimica Et Biophysica Sinica, 2016, 48, 17-26.	0.9	13
36	Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. Nature Communications, 2015, 6, 7396.	5.8	64
37	Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ÃŸ-lapachone. Cancer & Metabolism, 2015, 3, 12.	2.4	104
38	Pharmacological Inhibition of Protein Lipidation. Journal of Membrane Biology, 2015, 248, 929-941.	1.0	14

#	Article	IF	Citations
39	Drugging the Ral GTPase. Small GTPases, 2015, 6, 157-159.	0.7	3
40	Recent progress on MAP kinase pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4047-4056.	1.0	55
41	Divergent Roles of CAAX Motif-signaled Posttranslational Modifications in the Regulation and Subcellular Localization of Ral GTPases. Journal of Biological Chemistry, 2015, 290, 22851-22861.	1.6	37
42	Improving Prospects for Targeting RAS. Journal of Clinical Oncology, 2015, 33, 3650-3659.	0.8	89
43	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell, 2015, 28, 384-398.	7.7	243
44	Emerging Target Families: Intractable Targets. Handbook of Experimental Pharmacology, 2015, 232, 43-58.	0.9	9
45	Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. Acta Biochimica Et Biophysica Sinica, 2016, 48, 11-16.	0.9	17
46	Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403.	1.1	45
47	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. Journal of Cancer, 2016, 7, 1497-1514.	1.2	71
48	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. ELife, 2016, 5, .	2.8	191
49	Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Management and Research, 2016, 8, 21.	0.9	9
50	Multi-Center Evaluation of the Fully Automated PCR-Based Idyllaâ„¢ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0163444.	1.1	35
51	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers, 2016, 8, 45.	1.7	147
52	Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. Chemical Society Reviews, 2016, 45, 4929-4952.	18.7	150
53	MicroRNAs: Modulators of theRasOncogenes in Oral Cancer. Journal of Cellular Physiology, 2016, 231, 1424-1431.	2.0	22
54	Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy. Seminars in Cell and Developmental Biology, 2016, 58, 55-59.	2.3	17
55	Inhibitors of Rasâ€“SOS Interactions. ChemMedChem, 2016, 11, 814-821.	1.6	62
56	Translational Dynamics of Lipidated Ras Proteins in the Presence of Crowding Agents and Compatible Osmolytes. ChemPhysChem, 2016, 17, 2164-2169.	1.0	10

#	Article	IF	Citations
57	Identification of pyrazolopyridazinones as PDEÎ´ inhibitors. Nature Communications, 2016, 7, 11360.	5.8	137
58	Spatiotemporal imaging of small GTPases activity in live cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14348-14353.	3.3	13
59	The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. Scientific Reports, 2016, 6, 21949.	1.6	149
60	Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents. Scientific Reports, 2016, 6, 29741.	1.6	17
61	A Fungus-Specific Protein Domain Is Essential for RasA-Mediated Morphogenetic Signaling in Aspergillus fumigatus. MSphere, 2016, 1, .	1.3	14
62	Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer. Bioinformatics, 2016, 32, 1373-1379.	1.8	11
63	The Conundrum of Genetic â€œDriversâ€•in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	3.0	113
64	SUMO wrestling with Ras. Small GTPases, 2016, 7, 39-46.	0.7	5
65	Meet me in the cytoplasm: A role for p27Kip1in the control of H-Ras. Small GTPases, 2016, 7, 71-75.	0.7	3
66	Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Cancer Discovery, 2016, 6, 754-769.	7.7	132
67	Non-substrate based, small molecule inhibitors of the human isoprenylcysteine carboxyl methyltransferase. MedChemComm, 2016, 7, 1016-1021.	3.5	3
68	Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells. Oncology Letters, 2016, 12, 2463-2474.	0.8	11
69	Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation. Oncology Letters, 2016, 12, 2222-2226.	0.8	21
70	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature, 2016, 538, 114-117.	13.7	162
71	Mitochondrial Amino Acid Metabolism Provides Vulnerabilities inÂMutant KRAS-Driven Cancers. Gastroenterology, 2016, 151, 798-801.	0.6	3
72	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Seminars in Cell and Developmental Biology, 2016, 58, 108-117.	2.3	10
73	Selumetinib in the treatment of non-small-cell lung cancer. Future Oncology, 2016, 12, 2545-2560.	1.1	23
74	Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Molecular and Cellular Biology, 2016, 36, 2742-2754.	1.1	42

#	Article	IF	Citations
75	The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer, 2016, 16, 718-731.	12.8	447
76	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nature Reviews Clinical Oncology, 2016, 13, 750-765.	12.5	181
77	Quantitative Super-Resolution Microscopy for Cancer Biology and Medicine. Series in Cellular and Clinical Imaging, 2016, , 321-350.	0.2	0
78	Inhibition of Ral GTPases Using a Stapled Peptide Approach. Journal of Biological Chemistry, 2016, 291, 18310-18325.	1.6	20
79	Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective. Angewandte Chemie - International Edition, 2016, 55, 15982-15988.	7.2	14
80	Fortschritte bei der Rasâ€Inhibition aus medizinischâ€chemischer Perspektive. Angewandte Chemie, 2016, 128, 16215-16221.	1.6	0
81	WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. Endocrine-Related Cancer, 2016, 23, T135-T154.	1.6	17
82	The role of wild type RAS isoforms in cancer. Seminars in Cell and Developmental Biology, 2016, 58, 60-69.	2.3	104
83	Pancreatic cancer biology and genetics from an evolutionary perspective. Nature Reviews Cancer, 2016, 16, 553-565.	12.8	316
84	Functional Genomic Characterization of Cancer Genomes. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 237-246.	2.0	17
85	Signalling Pathways Controlling Cellular Actin Organization. Handbook of Experimental Pharmacology, 2016, 235, 153-178.	0.9	17
86	Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5703-5706.	1.0	23
87	Molecular Pathogenesis of Pancreatic Cancer. Progress in Molecular Biology and Translational Science, 2016, 144, 241-275.	0.9	113
88	Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. Journal of Molecular Biology, 2016, 428, 4723-4735.	2.0	30
89	Identification of Neutrophil Exocytosis Inhibitors (Nexinhibs), Small Molecule Inhibitors of Neutrophil Exocytosis and Inflammation. Journal of Biological Chemistry, 2016, 291, 25965-25982.	1.6	73
90	Therapeutic Approaches to RAS Mutation. Cancer Journal (Sudbury, Mass), 2016, 22, 165-174.	1.0	14
91	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	23
92	New structural and functional insight into the regulation of Ras. Seminars in Cell and Developmental Biology, 2016, 58, 70-78.	2.3	22

#	Article	IF	Citations
93	Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. Molecular and Cellular Proteomics, 2016, 15, 2924-2938.	2.5	79
94	A combinatorial strategy for treating KRAS-mutant lung cancer. Nature, 2016, 534, 647-651.	13.7	337
95	Molecular pathogenesis of pancreatic ductal adenocarcinoma. Diagnostic Histopathology, 2016, 22, 226-235.	0.2	1
96	Protease-Resistant and Cell-Permeable Double-Stapled Peptides Targeting the Rab8a GTPase. ACS Chemical Biology, 2016, 11, 2375-2382.	1.6	61
97	Searching for the Chokehold of NRAS Mutant Melanoma. Journal of Investigative Dermatology, 2016, 136, 1330-1336.	0.3	14
98	Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. Molecular Cancer, 2016, 15, 12.	7.9	42
99	Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors. Journal of the American Chemical Society, 2016, 138, 8332-8335.	6.6	69
100	Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. , 2016, 162, 69-85.		27
101	Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 182-187.	3.3	200
102	Ras Conformational Ensembles, Allostery, and Signaling. Chemical Reviews, 2016, 116, 6607-6665.	23.0	290
103	KRASpromoter oligonucleotide with decoy activity dimerizes into a unique topology consisting of two G-quadruplex units. Nucleic Acids Research, 2016, 44, 917-925.	6.5	47
104	Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences. Journal of Physical Chemistry B, 2016, 120, 667-679.	1.2	45
105	Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discovery, 2016, 6, 316-329.	7.7	578
106	Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science, 2016, 351, 604-608.	6.0	499
107	Protein prenylation: unique fats make their mark on biology. Nature Reviews Molecular Cell Biology, 2016, 17, 110-122.	16.1	393
108	A New View of Ras Isoforms in Cancers. Cancer Research, 2016, 76, 18-23.	0.4	87
109	Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When Itâ€™s Down. Cancer Cell, 2016, 29, 251-253.	7.7	56
110	RAS isoforms and mutations in cancer at a glance. Journal of Cell Science, 2016, 129, 1287-92.	1.2	606

#	Article	IF	Citations
111	Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence. Journal of Biological Chemistry, 2016, 291, 1703-1718.	1.6	31
112	Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs. , 2016, 162, 35-57.		16
113	K-Ras4B/calmodulin/PI3KÎ±: A promising new adenocarcinoma-specific drug target?. Expert Opinion on Therapeutic Targets, 2016, 20, 831-842.	1.5	29
114	Inhibition of Acid Sphingomyelinase Depletes Cellular Phosphatidylserine and Mislocalizes K-Ras from the Plasma Membrane. Molecular and Cellular Biology, 2016, 36, 363-374.	1.1	92
115	The renewed battle against RAS-mutant cancers. Cellular and Molecular Life Sciences, 2016, 73, 1845-1858.	2.4	33
116	G4 DNA in ras genes and its potential in cancer therapy. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 663-674.	0.9	45
117	Glutamate E15 and E171 are Hotspots in p60TRP-Related Cancer. Cancer Investigation, 2016, 34, 64-69.	0.6	1
118	Structures of aminoarabinose transferase ArnT suggest a molecular basis for lipid A glycosylation. Science, 2016, 351, 608-612.	6.0	94
119	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	9
120	Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9322-9329.	1.6	59
121	NORE1A is a double barreled Ras senescence effector that activates p53 and Rb. Cell Cycle, 2016, 15, 2263-2264.	1.3	7
122	Drug developers refocus efforts on RAS. Nature Biotechnology, 2016, 34, 217-218.	9.4	6
123	K-Ras protein as a drug target. Journal of Molecular Medicine, 2016, 94, 253-258.	1.7	85
124	Probe-free allele-specific copy number detection and analysis of tumors. Analytical Biochemistry, 2016, 497, 95-102.	1.1	3
125	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	1.0	56
126	Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Human Pathology, 2016, 51, 25-31.	1.1	35
127	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell, 2016, 29, 75-89.	7.7	191
128	RAS mutations â€“ for better or for worse in multiple myeloma?. Leukemia and Lymphoma, 2016, 57, 8-9.	0.6	3

#	Article	IF	Citations
129	Drugging Undruggable Molecular Cancer Targets. Annual Review of Pharmacology and Toxicology, 2016, 56, 23-40.	4.2	170
130	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95
131	Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer. Small GTPases, 2017, 8, 172-176.	0.7	17
132	A PDE6Î´â€KRas Inhibitor Chemotype with up to Seven Hâ€Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. Angewandte Chemie - International Edition, 2017, 56, 2423-2428.	7.2	78
133	The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Critical Reviews in Oncology/Hematology, 2017, 111, 7-19.	2.0	57
134	Mutant RAS Calms Stressed-Out Cancer Cells. Developmental Cell, 2017, 40, 120-122.	3.1	5
135	The RASâ€“Effector Interaction as a Drug Target. Cancer Research, 2017, 77, 221-226.	0.4	62
136	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Medical Oncology, 2017, 34, 26.	1.2	94
137	Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. Cancer Cell, 2017, 31, 5-19.	7.7	309
138	Screening-based approaches to identify small molecules that inhibit proteinâ€“protein interactions. Expert Opinion on Drug Discovery, 2017, 12, 293-303.	2.5	23
139	Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras. Cell, 2017, 168, 890-903.e15.	13.5	535
140	A PDE6Î´â€KRas Inhibitor Chemotype with up to Seven Hâ€Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. Angewandte Chemie, 2017, 129, 2463-2468.	1.6	6
141	Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer. Pharmacological Research, 2017, 117, 370-376.	3.1	14
142	Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation. Scientific Reports, 2017, 7, 41147.	1.6	19
143	Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biology and Therapy, 2017, 18, 158-165.	1.5	190
144	Probing the druggability of membrane-bound Rab5 by molecular dynamics simulations. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 434-443.	2.5	14
145	Improved treatment of nucleosides and nucleotides in the OPLS-AA force field. Chemical Physics Letters, 2017, 683, 276-280.	1.2	16
146	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. Cancer and Metastasis Reviews, 2017, 36, 53-75.	2.7	30

#	Article	IF	Citations
147	New tricks for human farnesyltransferase inhibitor: cancer and beyond. MedChemComm, 2017, 8, 841-854.	3.5	53
148	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	13.5	213
149	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. Journal of Biological Chemistry, 2017, 292, 4164-4175.	1.6	37
150	A fully automated procedure for the parallel, multidimensional purification and nucleotide loading of the human GTPases KRas, Rac1 and RalB. Protein Expression and Purification, 2017, 132, 75-84.	0.6	10
151	K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. Biochemical and Biophysical Research Communications, 2017, 484, 605-611.	1.0	89
152	Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Molecular Oncology, 2017, 11, 599-611.	2.1	32
153	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Reports, 2017, 18, 1543-1557.	2.9	95
154	miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis. Journal of Hepatology, 2017, 66, 1223-1230.	1.8	37
155	New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside. , 2017, , 67-91.		1
156	Repurposing bacterial toxins for intracellular delivery of therapeutic proteins. Biochemical Pharmacology, 2017, 142, 13-20.	2.0	39
157	Protein destabilization and loss of proteinâ€protein interaction are fundamental mechanisms in cblA â€type methylmalonic aciduria. Human Mutation, 2017, 38, 988-1001.	1.1	23
158	Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants. Proteins: Structure, Function and Bioinformatics, 2017, 85, 1618-1632.	1.5	44
159	Selective targeting of point-mutated KRAS through artificial microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4203-E4212.	3.3	38
160	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. Journal of Molecular Biology, 2017, 429, 1767-1786.	2.0	14
161	Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d. ACS Medicinal Chemistry Letters, 2017, 8, 732-736.	1.3	58
162	Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. Nature Communications, 2017, 8, 15090.	5.8	127
163	Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene, 2017, 36, 4975-4986.	2.6	62
164	Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Reports, 2017, 19, 969-980.	2.9	51

#	Article	IF	Citations
165	Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Research, 2017, 77, 3745-3757.	0.4	34
166	The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. EBioMedicine, 2017, 20, 79-97.	2.7	55
167	MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. Cell Death and Differentiation, 2017, 24, 1253-1262.	5.0	38
168	Autophagy and Ferroptosisâ€"What Is the Connection?. Current Pathobiology Reports, 2017, 5, 153-159.	1.6	133
169	Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2757-2761.	1.0	33
170	The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence. Cancer Letters, 2017, 400, 30-36.	3.2	12
171	Total Chemical Synthesis and Folding of All-<scp>l</scp> and All-<scp>d</scp> Variants of Oncogenic KRas(G12V). Journal of the American Chemical Society, 2017, 139, 7632-7639.	6.6	41
172	Phosphorylation Weakens but Does Not Inhibit Membrane Binding and Clustering of K-Ras4B. ACS Chemical Biology, 2017, 12, 1703-1710.	1.6	33
173	siRNA-loaded biodegradable nanocarriers for therapeutic MAPK1 silencing against cisplatin-induced ototoxicity. International Journal of Pharmaceutics, 2017, 528, 611-623.	2.6	20
174	Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity. Scientific Reports, 2017, 7, 3687.	1.6	23
175	Targeting the Ras palmitoylation/depalmitoylation cycle in cancer. Biochemical Society Transactions, 2017, 45, 913-921.	1.6	53
176	Drugging the 'undruggable' cancer targets. Nature Reviews Cancer, 2017, 17, 502-508.	12.8	620
177	Lung cancer samples preserved in liquid medium: One step beyond cytology. Diagnostic Cytopathology, 2017, 45, 915-921.	0.5	1
178	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine, 2017, 20, 39-49.	2.7	170
179	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	5.8	38
180	Targeting Aberrant Signaling in Myeloid Malignancies. Hematology/Oncology Clinics of North America, 2017, 31, 565-576.	0.9	3
181	Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. ACS Chemical Biology, 2017, 12, 1956-1962.	1.6	33
182	Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential. Expert Review of Proteomics, 2017, 14, 515-528.	1.3	7

#	Article	IF	Citations
183	Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression. Journal of the American Chemical Society, 2017, 139, 8522-8536.	6.6	140
184	A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Letters, 2017, 402, 61-70.	3.2	51
185	Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science Translational Medicine, 2017, 9, .	5.8	144
186	Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1668-1678.	1.4	15
187	High-resolution three-dimensional NMR structure of the KRAS proto-oncogene promoter reveals key features of a G-quadruplex involved in transcriptional regulation. Journal of Biological Chemistry, 2017, 292, 8082-8091.	1.6	64
188	The small GTPases Ras and Rheb studied by multidimensional NMR spectroscopy: structure and function. Biological Chemistry, 2017, 398, 577-588.	1.2	15
189	A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation. Journal of Biological Chemistry, 2017, 292, 4446-4456.	1.6	36
190	Application of Thiolâ€“yne/Thiolâ€“ene Reactions for Peptide and Protein Macrocyclizations. Chemistry - A European Journal, 2017, 23, 7087-7092.	1.7	36
191	Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Research, 2017, 27, 916-932.	5.7	103
192	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
193	Drugging RAS: Know the enemy. Science, 2017, 355, 1158-1163.	6.0	300
194	Structure-based development of PDEÎ´ inhibitors. Biological Chemistry, 2017, 398, 535-545.	1.2	20
195	Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Oncogene, 2017, 36, 3149-3158.	2.6	43
196	Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene, 2017, 36, 3263-3273.	2.6	7
197	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine, 2017, 23, 1362-1368.	15.2	462
198	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling, 2017, 10, .	1.6	51
199	Identification of a fragmented small GTPase capable of conditional effector binding. RSC Advances, 2017, 7, 12265-12268.	1.7	2
200	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	5.8	131

#	Article	IF	Citations
201	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	12.8	270
202	The role of Sâ€acylation in protein trafficking. Traffic, 2017, 18, 699-710.	1.3	40
203	Key signaling pathways in thyroid cancer. Journal of Endocrinology, 2017, 235, R43-R61.	1.2	95
204	A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Molecular Cancer Research, 2017, 15, 1764-1776.	1.5	61
205	Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discovery, 2017, 7, 1464-1479.	7.7	78
206	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administrationâ€“Approved Drugs. Pharmacological Reviews, 2017, 69, 479-496.	7.1	58
207	Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. Scientific Reports, 2017, 7, 12047.	1.6	19
208	A signal-based method for finding driver modules of breast cancer metastasis to the lung. Scientific Reports, 2017, 7, 10023.	1.6	5
209	Natural Compounds in Cancer Prevention: Effects of Coffee Extracts and Their Main Polyphenolic Component, 5â€Oâ€Caffeoylquinic Acid, on Oncogenic Ras Proteins. Chemistry - an Asian Journal, 2017, 12, 2457-2466.	1.7	46
210	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Annals of Oncology, 2017, 28, 2648-2657.	0.6	227
211	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. Cell Reports, 2017, 20, 999-1015.	2.9	77
212	New Approaches to Difficult Drug Targets: The Phosphatase Story. SLAS Discovery, 2017, 22, 1071-1083.	1.4	26
213	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie - International Edition, 2017, 56, 11539-11544.	7.2	100
214	An engineered protein antagonist of K-Ras/B-Raf interaction. Scientific Reports, 2017, 7, 5831.	1.6	55
215	Cellular expression, in-vitro and in-vivo confirmation of GAEC1 oncogenic properties in colon cancer. European Journal of Cell Biology, 2017, 96, 487-495.	1.6	6
216	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie, 2017, 129, 11697-11702.	1.6	22
217	KrÃ¼ppel-Like Factor 4 Promotes Pancreatic Acinar-to-Ductal Metaplasia and Tumor Initiation. Pancreas, 2017, 46, 139-142.	0.5	4
218	The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Reports, 2017, 20, 1692-1704.	2.9	608

#	Article	IF	Citations
219	Advances in the Genetics and Biology of Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 315-320.	1.0	17
220	Actionable gene-based classification toward precision medicine in gastric cancer. Genome Medicine, 2017, 9, 93.	3.6	59
221	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-ƙB pathways. Scientific Reports, 2017, 7, 15441.	1.6	49
222	Uncoupling the Oncogenic Engine. Cancer Research, 2017, 77, 6060-6064.	0.4	3
223	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Research, 2017, 77, 4238-4246.	0.4	95
224	Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. British Journal of Cancer, 2017, 117, 210-219.	2.9	40
225	Lessons Learned from Two Decades of Anticancer Drugs. Trends in Pharmacological Sciences, 2017, 38, 852-872.	4.0	74
226	Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene, 2017, 36, 6041-6048.	2.6	10
227	A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells. Cell Reports, 2017, 20, 427-438.	2.9	73
228	Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange. Nature Communications, 2017, 8, 16111.	5.8	77
229	PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion. Cell Reports, 2017, 19, 2657-2664.	2.9	31
230	Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin Î²1-driven Src-Akt bypass signaling. Oncogene, 2017, 36, 2543-2552.	2.6	44
231	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2414-2422.	3.2	148
232	Development of Pyridazinone Chemotypes Targeting the PDEÎ´ Prenyl Binding Site. Chemistry - A European Journal, 2017, 23, 6083-6093.	1.7	26
233	Inhibition of RAS function through targeting an allosteric regulatory site. Nature Chemical Biology, 2017, 13, 62-68.	3.9	237
234	Membrane orientation dynamics of lipid-modified small GTPases. Small GTPases, 2017, 8, 129-138.	0.7	36
235	Designed covalent allosteric modulators: an emerging paradigm in drug discovery. Drug Discovery Today, 2017, 22, 447-453.	3.2	44
236	Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling. Chemistry - A European Journal, 2017, 23, 1676-1685.	1.7	13

#	Article	IF	Citations
237	Ras and RASSF Effector Proteins. , 2017, , 3-23.		0
238	Search for Inhibitors of Ras-Driven Cancers. , 2017, , 135-154.		1
239	Extracellular Signal-Regulated Kinase (ERK1 and ERK2) Inhibitors. , 2017, , 233-249.		2
240	Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes. Cancer Informatics, 2017, 16, 117693511771194.	0.9	21
241	Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA). Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10755-E10762.	3.3	8
242	Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets. Nature Communications, 2017, 8, 2244.	5.8	56
243	Detecting mutant KRAS in liquid biopsies: a biomarker searching for a role. Annals of Oncology, 2017, 28, 677-678.	0.6	3
244	Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine. Oncotarget, 2017, 8, 82689-82699.	0.8	22
245	Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. Frontiers in Pharmacology, 2017, 08, 199.	1.6	45
246	Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs. Nutrients, 2017, 9, 185.	1.7	27
247	Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping. Sensors, 2017, 17, 831.	2.1	13
248	SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation. ELife, 2017, 6, .	2.8	62
249	Cancerâ€™s Achillesâ€™ Heel: Apoptosis and Necroptosis to the Rescue. International Journal of Molecular Sciences, 2017, 18, 23.	1.8	64
250	A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression. ELife, 2017, 6, .	2.8	71
251	Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. ELife, 2017, 6, .	2.8	167
252	Inhibition of prenylated KRAS in a lipid environment. PLoS ONE, 2017, 12, e0174706.	1.1	25
253	Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics. Journal of Experimental and Clinical Cancer Research, 2017, 36, 112.	3.5	23
254	Regulation of Ras signaling and function by plasma membrane microdomains. BioScience Trends, 2017, 11, 23-40.	1.1	13

#	Article	IF	Citations
255	Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa. BMC Evolutionary Biology, 2017, 17, 182.	3.2	14
256	Modeling of RAS complexes supports roles in cancer for less studied partners. BMC Biophysics, 2017, 10, 5.	4.4	10
257	Targeting Promoter Quadruplex Nucleic Acids for Cancer Therapy. , 2017, , 308-340.		3
258	Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Research, 2017, 6, 2184.	0.8	18
259	Allosteric Modulators. , 2017, , 276-296.		5
260	RAS Regulates the Transition from Naive to Primed Pluripotent Stem Cells. Stem Cell Reports, 2018, 10, 1088-1101.	2.3	27
261	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Krasâ€driven lung tumours. Journal of Pathology, 2018, 245, 101-113.	2.1	19
262	Interaction between Wnt/Î²-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of Î²-catenin and RAS by targeting the Wnt/Î²-catenin pathway. Npj Precision Oncology, 2018, 2, 5.	2.3	138
263	Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer. Endocrinology, 2018, 159, 1303-1327.	1.4	4
264	Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer. New Biotechnology, 2018, 45, 28-35.	2.4	20
265	Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 342-351.	1.3	13
266	Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins. Annual Review of Biophysics, 2018, 47, 107-124.	4.5	68
267	Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist. Internal and Emergency Medicine, 2018, 13, 313-318.	1.0	4
268	A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Molecular Carcinogenesis, 2018, 57, 1130-1143.	1.3	12
269	Impairment of Kâ€Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miRâ€143. Cancer Science, 2018, 109, 1455-1467.	1.7	36
270	Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. Cell Chemical Biology, 2018, 25, 705-717.e11.	2.5	79
271	Chemical probes and drug leads from advances in synthetic planning and methodology. Nature Reviews Drug Discovery, 2018, 17, 333-352.	21.5	182
272	ERF deletion rescues RAS deficiency in mouse embryonic stem cells. Genes and Development, 2018, 32, 568-576.	2.7	13

#	Article	IF	Citations
273	c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell, 2018, 33, 217-228.e4.	7.7	93
274	Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell, 2018, 172, 578-589.e17.	13.5	834
275	The diamond anniversary of tissue transglutaminase: a protein of many talents. Drug Discovery Today, 2018, 23, 575-591.	3.2	38
276	Interaction of KRas4B protein with C6-ceramide containing lipid model membranes. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1008-1014.	1.4	2
277	Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death and Disease, 2018, 9, 216.	2.7	41
278	Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT. Nature, 2018, 553, 526-529.	13.7	33
279	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181.	21.5	294
280	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
281	A small molecule inhibitor of Rheb selectively targets mTORC1 signaling. Nature Communications, 2018, 9, 548.	5.8	68
282	Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b. ACS Central Science, 2018, 4, 71-80.	5.3	25
283	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research, 2018, 78, 985-1002.	0.4	35
284	Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele. Biochemistry, 2018, 57, 1380-1389.	1.2	6
285	Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Research, 2018, 28, 374-382.	2.4	59
286	Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer. Journal of Cell Communication and Signaling, 2018, 12, 513-527.	1.8	36
287	Posttranslational Modifications of RAS Proteins. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031484.	2.9	66
288	A modified gene trap approach for improved high-throughput cancer drug discovery. Oncogene, 2018, 37, 4226-4238.	2.6	5
289	Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients. BMC Bioinformatics, 2018, 19, 40.	1.2	14
290	Metabolism in Pancreatic Cancer. , 2018, , 1379-1400.		1

#	Article	IF	Citations
291	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. , 2018, , 1577-1611.		1
292	Mapping Effectorâ€"Phenotype Landscapes in KRAS-Driven Cancers. Trends in Cancer, 2018, 4, 333-335.	3.8	0
293	The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology, 2018, 14, 431-441.	3.9	629
294	A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy. Drug Discovery Today, 2018, 23, 1344-1356.	3.2	24
295	Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Small GTPases, 2018, 9, 452-456.	0.7	11
296	Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. Journal of Cellular Physiology, 2018, 233, 2058-2066.	2.0	61
297	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene, 2018, 37, 821-832.	2.6	55
298	Discovery of hidden allosteric sites as novel targets for allosteric drug design. Drug Discovery Today, 2018, 23, 359-365.	3.2	92
299	Targeting the Architecture of Deregulated Protein Complexes in Cancer. Advances in Protein Chemistry and Structural Biology, 2018, 111, 101-132.	1.0	5
300	The promise of signal transduction in genetically driven sarcomas of the nerve. Experimental Neurology, 2018, 299, 317-325.	2.0	15
301	Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031518.	2.9	63
302	Efforts to Develop KRAS Inhibitors. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031864.	2.9	27
303	The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20160525.	1.8	78
304	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031435.	2.9	563
305	Kras and Tumor Immunity: Friend or Foe?. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031849.	2.9	62
306	RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. Pharmacological Reviews, 2018, 70, 1-11.	7.1	78
307	Platinum coordination compounds with potent anticancer activity. Coordination Chemistry Reviews, 2018, 375, 148-163.	9.5	142
308	Transcribing malignancy: transcription-associated genomic instability in cancer. Oncogene, 2018, 37, 971-981.	2.6	15

#	Article	IF	Citations
309	DA-Raf, a dominant-negative antagonist of the Rasâ€“ERK pathway, is a putative tumor suppressor. Experimental Cell Research, 2018, 362, 111-120.	1.2	6
310	Fluorescent light-up acridine orange derivatives bind and stabilize KRAS-22RT G-quadruplex. Biochimie, 2018, 144, 144-152.	1.3	41
311	From Ras to Rap and Back, a Journey of 35 Years. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031468.	2.9	16
312	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1007-1016.	0.8	67
313	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Translational Lung Cancer Research, 2018, 7, 464-486.	1.3	11
314	MicroRNAâ€'143â€'3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the kâ€'Ras/Raf/MEK/ERK signaling pathway. International Journal of Oncology, 2018, 54, 689-701.	1.4	12
315	A model for RAS mutation patterns in cancers: finding the sweet spot. Nature Reviews Cancer, 2018, 18, 767-777.	12.8	266
316	Paring down to the essentials. Science, 2018, 362, 904-904.	6.0	0
317	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British Journal of Cancer, 2018, 119, 1471-1476.	2.9	74
318	The dual role of HMGB1 in pancreatic cancer. Journal of Pancreatology, 2018, 1, 19-24.	0.3	16
319	Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. Oncotarget, 2018, 9, 22749-22768.	0.8	8
320	Targeting KRAS Mutant CMS3 Subtype by Metabolic Inhibitors. Advances in Experimental Medicine and Biology, 2018, 1110, 23-34.	0.8	7
321	Enhanced nanoparticle delivery exploiting tumour-responsive formulations. Cancer Nanotechnology, 2018, 9, 10.	1.9	30
322	Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression. Molecular Therapy - Oncolytics, 2018, 11, 90-101.	2.0	11
323	Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. Cell Reports, 2018, 25, 3545-3553.e2.	2.9	25
324	Post-Translational Modification and Subcellular Distribution of Rac1: An Update. Cells, 2018, 7, 263.	1.8	47
325	Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. Journal of Experimental and Clinical Cancer Research, 2018, 37, 302.	3.5	27
326	Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. Cancers, 2018, 10, 478.	1.7	30

#	Article	IF	Citations
327	GSK3 suppression upregulates Î²-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications, 2018, 9, 5154.	5.8	84
328	Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma. EBioMedicine, 2018, 36, 196-208.	2.7	17
329	Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. Molecular Cancer Therapeutics, 2018, 17, 2495-2506.	1.9	8
330	HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. International Journal of Oncology, 2018, 53, 725-736.	1.4	22
331	Therapeutic strategies to target RAS-mutant cancers. Nature Reviews Clinical Oncology, 2018, 15, 709-720.	12.5	274
332	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. Journal of Cancer, 2018, 9, 3394-3399.	1.2	5
333	Codon usage regulates human KRAS expression at both transcriptional and translational levels. Journal of Biological Chemistry, 2018, 293, 17929-17940.	1.6	43
334	The small organic molecule C19 binds and strengthens the KRAS4b-PDEÎ´ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. BMC Cancer, 2018, 18, 1056.	1.1	15
335	Targeted Intracellular Delivery of Antibodies: The State of the Art. Frontiers in Pharmacology, 2018, 9, 1208.	1.6	144
336	Methionine 170 is an Environmentally Sensitive Membrane Anchor in the Disordered HVR of K-Ras4B. Journal of Physical Chemistry B, 2018, 122, 10086-10096.	1.2	22
337	Quantitative Measurement of Intrinsic GTP Hydrolysis for Carcinogenic Glutamine 61 Mutants in H-Ras. Biochemistry, 2018, 57, 6356-6366.	1.2	24
338	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. Diagnostic Pathology, 2018, 13, 78.	0.9	15
339	Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis. Reproductive Medicine and Biology, 2018, 17, 369-397.	1.0	35
340	The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. Endocrine Reviews, 2018, 39, 676-700.	8.9	157
341	Programmable protein circuits in living cells. Science, 2018, 361, 1252-1258.	6.0	242
342	Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target Cells. Molecular Pharmaceutics, 2018, 15, 5217-5226.	2.3	16
343	Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nature Communications, 2018, 9, 3646.	5.8	56
344	KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. Cancer Letters, 2018, 438, 174-186.	3.2	38

#	Article	IF	Citations
345	Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma. Journal of Cancer, 2018, 9, 1-12.	1.2	4
346	Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Science Signaling, 2018, 11, .	1.6	38
347	First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2018, 61, 8353-8373.	2.9	17
348	Ras proteins as therapeutic targets. Biochemical Society Transactions, 2018, 46, 1303-1311.	1.6	4
349	Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine, 2018, 24, 968-977.	15.2	196
350	Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nature Medicine, 2018, 24, 954-960.	15.2	278
351	Small-Molecule Screening for Genetic Diseases. Annual Review of Genomics and Human Genetics, 2018, 19, 263-288.	2.5	9
352	Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. Neoplasia, 2018, 20, 668-677.	2.3	8
353	ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. Clinical Cancer Research, 2018, 24, 4044-4055.	3.2	36
354	Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition. Cancer Research, 2018, 78, 3899-3912.	0.4	29
355	Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor. ACS Medicinal Chemistry Letters, 2018, 9, 557-562.	1.3	19
356	Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. Journal of Medicinal Chemistry, 2018, 61, 6002-6017.	2.9	33
357	Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 2018, 78, 4642-4657.	0.4	60
358	Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. SLAS Discovery, 2018, 23, 850-861.	1.4	11
359	Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. Advances in Clinical Chemistry, 2018, 83, 53-72.	1.8	22
360	An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth. Journal of Biological Chemistry, 2018, 293, 13696-13706.	1.6	20
361	MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Science Translational Medicine, 2018, 10, .	5.8	104
362	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research, 2018, 24, 4854-4864.	3.2	49

#	Article	IF	Citations
363	Desmoplakin maintains gap junctions by inhibiting Ras/MAPK and lysosomal degradation of connexin-43. Journal of Cell Biology, 2018, 217, 3219-3235.	2.3	41
364	Loss of protein phosphatase 6 in mouse keratinocytes enhances Kâ€ras^{G12D}â€driven tumor promotion. Cancer Science, 2018, 109, 2178-2187.	1.7	13
365	The microtubule-associated protein PRC1 is a potential therapeutic target for lung cancer. Oncotarget, 2018, 9, 4985-4997.	0.8	13
366	Design of synthetic materials for intracellular delivery of RNAs: From siRNA-mediated gene silencing to CRISPR/Cas gene editing. Nano Research, 2018, 11, 5310-5337.	5.8	31
367	ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL. BMC Cancer, 2018, 18, 599.	1.1	24
368	ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. Oral Oncology, 2018, 84, 95-103.	0.8	29
369	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. International Journal of Molecular Sciences, 2018, 19, 1878.	1.8	34
370	A New Strategy to Control and Eradicate â€œUndruggableâ€•Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 2018, 10, 142.	1.7	17
371	Allosteric Inhibitor of KRas Identified Using a Barcoded Assay Microchip Platform. Analytical Chemistry, 2018, 90, 8824-8830.	3.2	11
372	BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. ELife, 2018, 7, .	2.8	41
373	6-Methoxy-5,6-dihydrochelerythrine suppresses PANC-1 cells by down-regulating the Ras/Raf/Mek/Erk pathway. Phytochemistry Letters, 2018, 27, 108-113.	0.6	3
374	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 56.	1.8	54
375	The curious case of GÎ±s gain-of-function in neoplasia. BMC Cancer, 2018, 18, 293.	1.1	17
376	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of Experimental and Clinical Cancer Research, 2018, 37, 57.	3.5	140
377	CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma. Biological Research, 2018, 51, 1.	1.5	40
378	A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Molecular Cancer Therapeutics, 2018, 17, 1773-1780.	1.9	8
379	The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 67-75.	3.3	93
380	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. Laboratory Investigation, 2018, 98, 968-976.	1.7	33

#	Article	IF	Citations
381	RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis. Cancer Research, 2018, 78, 2614-2623.	0.4	28
382	The role of the long nonâ€coding RNA HOXA11â€AS in promoting proliferation and metastasis of malignant tumors. Cell Biology International, 2018, 42, 1596-1601.	1.4	16
383	Recent Advances and Perspectives in Cancer Drug Design. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1233-1250.	0.3	38
384	Phosphorylation promotes binding affinity of Rap-Raf complex by allosteric modulation of switch loop dynamics. Scientific Reports, 2018, 8, 12976.	1.6	10
385	Inhibition of K-RAS4B by a Unique Mechanism of Action: Stabilizing Membrane-Dependent Occlusion of the Effector-Binding Site. Cell Chemical Biology, 2018, 25, 1327-1336.e4.	2.5	72
386	Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS. ACS Medicinal Chemistry Letters, 2018, 9, 941-946.	1.3	24
387	Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation. Molecules, 2018, 23, 1958.	1.7	40
388	Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells. Scientific Reports, 2018, 8, 11879.	1.6	30
389	Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. Journal of Biological Chemistry, 2018, 293, 14891-14904.	1.6	95
390	A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Letters, 2018, 431, 171-181.	3.2	96
391	Synthesis of Ras proteins and their application in biofunctional studies. Chinese Chemical Letters, 2018, 29, 1043-1050.	4.8	8
392	Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity. European Journal of Cancer, 2018, 99, 37-48.	1.3	26
393	Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of Î²-catenin signaling. Experimental and Molecular Medicine, 2018, 50, 1-10.	3.2	9
394	KRAS: Reasons for optimism in lung cancer. European Journal of Cancer, 2018, 99, 20-27.	1.3	43
395	Afatinib restrains K-RASâ€“driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	5.8	99
396	Cutaneous <scp>pH</scp> landscape as a facilitator of melanoma initiation and progression. Acta Physiologica, 2019, 225, e13105.	1.8	11
397	Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2415-2429.	2.0	0
398	A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2019, 143, 183-189.	1.2	6

#	Article	IF	Citations
399	Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics. Journal of Chemical Information and Modeling, 2019, 59, 3955-3967.	2.5	23
400	A Guanidylâ€Based Bivalent Peptidomimetic Inhibits Kâ€Ras Prenylation and Association with câ€Raf. Chemistry - A European Journal, 2019, 25, 13531-13536.	1.7	7
401	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	1.2	285
402	Ras Downstream Effector GGCT Alleviates Oncogenic Stress. IScience, 2019, 19, 256-266.	1.9	12
403	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers, 2019, 11, 1133.	1.7	47
404	Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS-Mutant Cancer Cells. Cancer Research, 2019, 79, 4855-4868.	0.4	15
405	Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRAS^{G12C}. ACS Medicinal Chemistry Letters, 2019, 10, 1302-1308.	1.3	66
406	Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells, 2019, 8, 878.	1.8	17
407	Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth. Cell Reports, 2019, 28, 1845-1859.e5.	2.9	93
408	The Role and Function of Ras-association domain family in Cancer: A Review. Genes and Diseases, 2019, 6, 378-384.	1.5	47
409	Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17290-17297.	3.3	16
410	RAS in pancreatic cancer. Biochemical Society Transactions, 2019, 47, 961-972.	1.6	51
411	MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene, 2019, 38, 7266-7277.	2.6	17
412	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis, 2019, 8, 45.	2.1	38
413	Deactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design. ACS Catalysis, 2019, 9, 7188-7196.	5.5	77
414	Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry. Biochemistry, 2019, 58, 3396-3405.	1.2	25
415	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS Journal, 2019, 286, 3510-3539.	2.2	33
416	A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. Scientific Reports, 2019, 9, 10929.	1.6	23

#	Article	IF	Citations
417	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
418	Acylpeptide hydrolase is a novel regulator of KRAS plasma membrane localization and function. Journal of Cell Science, 2019, 132, .	1.2	16
419	Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. Frontiers in Oncology, 2019, 9, 521.	1.3	35
420	The Ras switch in structural and historical perspective. Biological Chemistry, 2019, 401, 143-163.	1.2	51
421	The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb. International Journal of Molecular Sciences, 2019, 20, 4917.	1.8	11
422	KRAS regulation by small non-coding RNAs and SNARE proteins. Nature Communications, 2019, 10, 5118.	5.8	17
423	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. Frontiers in Oncology, 2019, 9, 1049.	1.3	24
424	Novel Antrodia cinnamomea Extract Reduced Cancer Stem-Like Phenotype Changes and Resensitized KRAS-Mutant Colorectal Cancer via a MicroRNA-27a Pathway. Cancers, 2019, 11, 1657.	1.7	4
425	KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2019, 19, 1131-1140.	1.5	9
426	Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine, 2019, 49, 72-81.	2.7	33
427	Antitumor activity of an engineered decoy receptor targeting CLCF1â€“CNTFR signaling in lung adenocarcinoma. Nature Medicine, 2019, 25, 1783-1795.	15.2	43
428	All over the place: deciphering HRAS signaling from different subcellular compartments. Molecular and Cellular Oncology, 2019, 6, e1605821.	0.3	0
429	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6742-6755.	3.2	45
430	Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis . International Journal of Nanomedicine, 2019, Volume 14, 6589-6600.	3.3	23
431	In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors. Journal of Controlled Release, 2019, 311-312, 245-256.	4.8	28
432	A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas. Scientific Reports, 2019, 9, 13396.	1.6	27
433	TRPML1 and RAS-driven cancers â€“ exploring a link with great therapeutic potential. Channels, 2019, 13, 374-381.	1.5	16
434	Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2545-2550.	3.3	96

#	Article	IF	Citations
435	Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy. Molecules, 2019, 24, 429.	1.7	214
436	Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell, 2019, 176, 1113-1127.e16.	13.5	74
437	The genetic changes of Wilms tumour. Nature Reviews Nephrology, 2019, 15, 240-251.	4.1	159
438	MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4508-4517.	3.3	97
439	Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RASâ€“SOS1 interaction. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2551-2560.	3.3	262
440	Progress in targeting RAS with small molecule drugs. Biochemical Journal, 2019, 476, 365-374.	1.7	53
441	B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene, 2019, 38, 1324-1339.	2.6	10
442	The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases. Journal of Biological Chemistry, 2019, 294, 11793-11804.	1.6	13
443	KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. Nature Communications, 2019, 10, 2607.	5.8	66
444	KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stemâ€“Like Cells and Promotes Metastasis. Molecular Cancer Research, 2019, 17, 1945-1957.	1.5	31
445	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clinical Cancer Research, 2019, 25, 5984-5996.	3.2	46
446	Drugging K-RasG12C through covalent inhibitors: Mission possible?. , 2019, 202, 1-17.		63
447	Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation. British Journal of Cancer, 2019, 121, 37-50.	2.9	41
448	KRAS ^{G12C} inhibition produces a driver-limited state revealing collateral dependencies. Science Signaling, 2019, 12, .	1.6	123
449	Effectiveness of Dance Movement Therapy in the Treatment of Adults With Depression: A Systematic Review With Meta-Analyses. Frontiers in Psychology, 2019, 10, 936.	1.1	77
450	Dissociation of the Signaling Protein Kâ€Ras4B from Lipid Membranes Induced by a Molecular Tweezer. Chemistry - A European Journal, 2019, 25, 9827-9833.	1.7	5
451	Advancements in CRISPR/Cas9 technologyâ€”Focusing on cancer therapeutics and beyond. Seminars in Cell and Developmental Biology, 2019, 96, 13-21.	2.3	19
452	RAS Mutations Are Not Created Equal. Cancer Discovery, 2019, 9, 696-698.	7.7	20

#	Article	IF	Citations
453	SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nature Communications, 2019, 10, 2532.	5.8	53
454	GTP Hydrolysis Without an Active Site Base: A Unifying Mechanism for Ras and Related GTPases. Journal of the American Chemical Society, 2019, 141, 10684-10701.	6.6	44
455	Time-resolved protein activation by proximal decaging in living systems. Nature, 2019, 569, 509-513.	13.7	146
456	Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx. Developmental Cell, 2019, 50, 57-72.e6.	3.1	74
457	Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. International Journal of Molecular Sciences, 2019, 20, 2167.	1.8	472
458	K-Ras^{G12D} Has a Potential Allosteric Small Molecule Binding Site. Biochemistry, 2019, 58, 2542-2554.	1.2	33
459	Advances in targeted degradation of endogenous proteins. Cellular and Molecular Life Sciences, 2019, 76, 2761-2777.	2.4	73
460	Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells. Trends in Endocrinology and Metabolism, 2019, 30, 357-368.	3.1	52
461	Multiâ€target, ensembleâ€based virtual screening yields novel allosteric <scp>KRAS</scp> inhibitors at high success rate. Chemical Biology and Drug Design, 2019, 94, 1441-1456.	1.5	33
462	Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR. Science Advances, 2019, 5, eaav8945.	4.7	18
463	Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges. Cells, 2019, 8, 255.	1.8	58
464	IKKÎ² targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target. Lung Cancer, 2019, 130, 169-178.	0.9	9
465	Protein-Catalyzed Capture Agents. Chemical Reviews, 2019, 119, 9950-9970.	23.0	27
466	<scp>ADAM</scp> 17 selectively activates the <scp>IL</scp> â€6 transâ€signaling/ <scp>ERK MAPK</scp> axis in <scp>KRAS</scp> â€addicted lung cancer. EMBO Molecular Medicine, 2019, 11, .	3.3	65
467	A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium. American Journal of Surgical Pathology, 2019, 43, 389-398.	2.1	71
468	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	15.2	476
469	Characterisation of the Ral GTPase inhibitor RBC8 in human and mouse platelets. Cellular Signalling, 2019, 59, 34-40.	1.7	7
470	Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release. ACS Nano, 2019, 13, 4049-4063.	7.3	105

#	Article	IF	Citations
471	Targeting the untargetable KRAS in cancer therapy. Acta Pharmaceutica Sinica B, 2019, 9, 871-879.	5.7	261
472	Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Letters, 2019, 451, 11-22.	3.2	28
473	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine, 2019, 41, 711-716.	2.7	142
474	An Integrated Global Analysis of Compartmentalized HRAS Signaling. Cell Reports, 2019, 26, 3100-3115.e7.	2.9	36
475	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	5.8	42
476	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports, 2019, 27, 631-647.e5.	2.9	9
477	Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Molecular Cancer, 2019, 18, 85.	7.9	41
478	Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach. PLoS ONE, 2019, 14, e0215247.	1.1	3
479	Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS Computational Biology, 2019, 15, e1006658.	1.5	83
480	Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Research, 2019, 47, 4375-4392.	6.5	65
481	5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma. Medicina (Lithuania), 2019, 55, 85.	0.8	18
482	Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International, 2019, 2019, 1-12.	0.9	5
483	LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei. Fish and Shellfish Immunology, 2019, 88, 150-160.	1.6	19
484	Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses. ACS Chemical Biology, 2019, 14, 325-331.	1.6	15
485	Drug Design of â€œUndruggableâ€•Targets. Chinese Journal of Chemistry, 2019, 37, 501-512.	2.6	8
486	Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers. International Journal of Molecular Sciences, 2019, 20, 774.	1.8	21
487	Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis. Archives of Pathology and Laboratory Medicine, 2019, 143, 628-633.	1.2	14
488	Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nature Nanotechnology, 2019, 14, 388-397.	15.6	107

#	Article	IF	Citations
489	K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function. Journal of Biological Chemistry, 2019, 294, 7068-7084.	1.6	47
490	Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. Journal of Medicinal Chemistry, 2019, 62, 6405-6421.	2.9	124
491	Polymeric Micelles in Management of Lung Cancer. , 2019, , 193-216.		2
492	Identification of a new inhibitor of KRASâ€PDEÎ´ interaction targeting KRAS mutant nonsmall cell lung cancer. International Journal of Cancer, 2019, 145, 1334-1345.	2.3	29
493	Involvement of ERK1/2-mediated ELK1/CHOP/DR5 pathway in 6-(methylsulfinyl)hexyl isothiocyanate-induced apoptosis of colorectal cancer cells. Bioscience, Biotechnology and Biochemistry, 2019, 83, 960-969.	0.6	12
494	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Advances, 2019, 3, 3214-3227.	2.5	19
495	Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers, 2019, 11, 2010.	1.7	38
497	The Impact of PI3â€kinase/RAS Pathway Cooperating Mutations in the Evolution of KMT2Aâ€rearranged Leukemia. HemaSphere, 2019, 3, e195.	1.2	9
498	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Journal of Hematology and Oncology, 2019, 12, 130.	6.9	64
499	RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer. Frontiers in Oncology, 2019, 9, 1255.	1.3	47
500	Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. Cells, 2019, 8, 1557.	1.8	7
501	Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta, Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway. Journal of Natural Products, 2019, 82, 3357-3365.	1.5	20
502	Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. Pancreas, 2019, 48, 894-903.	0.5	8
503	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 2019, 38, 622-636.	2.6	37
504	Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. Molecular Cancer Research, 2019, 17, 199-211.	1.5	44
505	Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule. Journal of Medicinal Chemistry, 2019, 62, 306-316.	2.9	29
506	PDEÎ´ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. International Journal of Cancer, 2019, 144, 767-776.	2.3	24
507	RNA Interference-Based Cancer Drugs: The Roadblocks, and the â€œDeliveryâ€•of the Promise. Nucleic Acid Therapeutics, 2019, 29, 61-66.	2.0	27

#	Article	IF	Citations
508	Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane. Journal of Biological Chemistry, 2019, 294, 2193-2207.	1.6	38
509	Fragment-based drug discovery of triazole inhibitors to block PDEÎ´-RAS protein-protein interaction. European Journal of Medicinal Chemistry, 2019, 163, 597-609.	2.6	20
510	Probing Colocalization of Nâ€Ras and Kâ€Ras4B Lipoproteins in Model Biomembranes. ChemBioChem, 2019, 20, 1190-1195.	1.3	4
511	Targeting the Î±4â€“Î±5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene, 2019, 38, 2984-2993.	2.6	49
512	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68
513	Fractionated radiotherapy might induce epithelialâ€mesenchymal transition and radioresistance in a cellular context manner. Journal of Cellular Biochemistry, 2019, 120, 8601-8610.	1.2	19
514	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	1.0	28
515	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications, 2019, 10, 224.	5.8	66
516	Toward Multi-Targeted Platinum and Ruthenium Drugsâ€”A New Paradigm in Cancer Drug Treatment Regimens?. Chemical Reviews, 2019, 119, 1058-1137.	23.0	463
517	Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death and Differentiation, 2019, 26, 1365-1378.	5.0	10
518	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	3.2	175
519	Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer Biology and Therapy, 2019, 20, 21-30.	1.5	14
520	Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. Small GTPases, 2019, 10, 441-448.	0.7	5
521	Targeting the Î±4-Î±5 interface of RAS results in multiple levels of inhibition. Small GTPases, 2019, 10, 378-387.	0.7	29
522	Direct inhibition of RAS: Quest for the Holy Grail?. Seminars in Cancer Biology, 2019, 54, 138-148.	4.3	63
523	Challenges in Ras therapeutics in pancreatic cancer. Seminars in Cancer Biology, 2019, 54, 101-108.	4.3	29
524	Blocking Ras inhibition as an antitumor strategy. Seminars in Cancer Biology, 2019, 54, 91-100.	4.3	35
525	Targeting the RAS-dependent chemoresistance: The Warburg connection. Seminars in Cancer Biology, 2019, 54, 80-90.	4.3	31

#	Article	IF	Citations
526	New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Seminars in Cancer Biology, 2019, 54, 162-173.	4.3	16
527	Ras and Rap1: A tale of two GTPases. Seminars in Cancer Biology, 2019, 54, 29-39.	4.3	121
528	Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation. Small GTPases, 2020, 11, 271-279.	0.7	3
529	Targeting Ras signaling in AML: RALB is a small GTPase with big potential. Small GTPases, 2020, 11, 39-44.	0.7	8
530	Targeting der kleinen GTPasen Ã¼ber ihre regulatorischen Proteine. Angewandte Chemie, 2020, 132, 6402-6428.	1.6	1
531	Targeting the Small GTPase Superfamily through Their Regulatory Proteins. Angewandte Chemie - International Edition, 2020, 59, 6342-6366.	7.2	87
532	Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis. Small GTPases, 2020, 11, 312-319.	0.7	1
533	LINC00265 promotes colorectal tumorigenesis via ZMIZ2 and USP7-mediated stabilization of Î²-catenin. Cell Death and Differentiation, 2020, 27, 1316-1327.	5.0	55
534	Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. Oncogene, 2020, 39, 1152-1164.	2.6	12
535	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	12.5	195
536	EPHA2 feedback activation limits the response to PDEÎ´ inhibition in KRAS-dependent cancer cells. Acta Pharmacologica Sinica, 2020, 41, 270-277.	2.8	4
537	Biological and clinical relevance of metastasisâ€associated long noncoding RNAs in esophageal squamous cell carcinoma: A systematic review. Journal of Cellular Physiology, 2020, 235, 848-868.	2.0	21
538	Therapeutic targeting of RAS: New hope for drugging the â€œundruggableâ€• Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118570.	1.9	77
539	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discovery, 2020, 10, 104-123.	7.7	131
540	RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica, 2020, 105, 2316-2326.	1.7	12
541	Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo. Pathology and Oncology Research, 2020, 26, 1957-1969.	0.9	10
542	STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. Cancers, 2020, 12, 119.	1.7	9
543	Advancing <scp>RAS/RASopathy</scp> therapies: An NCIâ€sponsored intramural and extramural collaboration for the study of <scp>RASopathies</scp>. American Journal of Medical Genetics, Part A, 2020, 182, 866-876.	0.7	40

#	Article	IF	Citations
544	In-silico design of peptide inhibitors of K-Ras target in cancer disease. Journal of Biomolecular Structure and Dynamics, 2020, 38, 5488-5499.	2.0	31
545	Discovery of a Covalent Inhibitor of KRAS^{G12C} (AMG 510) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 2020, 63, 52-65.	2.9	403
546	Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance. Journal of Medicinal Chemistry, 2020, 63, 186-204.	2.9	26
547	Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5â€WT1â€Eâ€cadherin signalling pathway in pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 1370-1382.	1.6	15
548	Dominant-negative antagonists of the Rasâ€“ERK pathway: DA-Raf and its related proteins generated by alternative splicing of Raf. Experimental Cell Research, 2020, 387, 111775.	1.2	6
549	ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. Theranostics, 2020, 10, 151-165.	4.6	23
550	Targeting RAS in pediatric cancer: is it becoming a reality?. Current Opinion in Pediatrics, 2020, 32, 48-56.	1.0	13
551	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. International Journal of Cancer, 2020, 146, 3450-3460.	2.3	14
552	A chemically-controlled system for activating RAS GTPases. Methods in Enzymology, 2020, 633, 103-117.	0.4	0
553	CRISPR Diagnosis and Therapeutics with Single Base Pair Precision. Trends in Molecular Medicine, 2020, 26, 337-350.	3.5	30
554	Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. International Journal of Molecular Sciences, 2020, 21, 141.	1.8	15
555	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Journal of Hematology and Oncology, 2020, 13, 130.	6.9	166
556	Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Molecular Oncology, 2020, 14, 3153-3168.	2.1	7
557	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell, 2020, 38, 788-802.	7.7	273
558	Hepatic oxidative stress, up-regulation of pro-inflammatory cytokines, apoptotic and oncogenic markers following 2-methoxyethanol administrations in rats. Biochemistry and Biophysics Reports, 2020, 24, 100806.	0.7	11
559	Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach. Journal of Biomolecular Structure and Dynamics, 2022, 40, 1571-1585.	2.0	16
560	Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Visceral Medicine, 2020, 36, 373-380.	0.5	3
561	SOS GEFs in health and disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188445.	3.3	44

#	Article	IF	Citations
562	Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy. Advanced Materials, 2020, 32, e2002440.	11.1	160
563	Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. Cancer Letters, 2020, 493, 80-90.	3.2	14
564	Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample. Medicine (United States), 2020, 99, e21171.	0.4	2
565	Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers. International Journal of Molecular Sciences, 2020, 21, 5023.	1.8	8
566	Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System. Cell Chemical Biology, 2020, 27, 1164-1180.e5.	2.5	42
567	Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System. Cell Chemical Biology, 2020, 27, 1151-1163.e6.	2.5	43
568	KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews, 2020, 89, 102070.	3.4	136
569	Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods. Journal of Medicinal Chemistry, 2020, 63, 8325-8337.	2.9	20
570	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer . Journal of Experimental Pharmacology, 2020, Volume 12, 475-485.	1.5	7
571	PI3KÎ³ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibitionâ€"Moving Towards Cell Specific PI3K Targeting?. Frontiers in Immunology, 2020, 11, 585070.	2.2	10
572	Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer. Cancers, 2020, 12, 3413.	1.7	12
573	Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. Journal of Medicinal Chemistry, 2020, 63, 14404-14424.	2.9	56
574	Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives. Biomolecules, 2020, 10, 1535.	1.8	8
575	CDK4/6 and MAPKâ€"Crosstalk as Opportunity for Cancer Treatment. Pharmaceuticals, 2020, 13, 418.	1.7	28
576	Distinct metabolic preference of atypical KRAS mutant. Annals of Translational Medicine, 2020, 8, 1326-1326.	0.7	0
577	Proximal Protein Interaction Landscape of RAS Paralogs. Cancers, 2020, 12, 3326.	1.7	6
578	M-Ras is Muscle-Ras, Moderate-Ras, Mineral-Ras, Migration-Ras, and Many More-Ras. Experimental Cell Research, 2020, 397, 112342.	1.2	7
579	Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. Cancers, 2020, 12, 3511.	1.7	13

#	Article	IF	Citations
580	Role of Epithelialâ€“Mesenchymal Plasticity in Pseudomyxoma Peritonei: Implications for Locoregional Treatments. International Journal of Molecular Sciences, 2020, 21, 9120.	1.8	6
581	Small molecule inhibitors of RAS proteins with oncogenic mutations. Cancer and Metastasis Reviews, 2020, 39, 1107-1126.	2.7	15
582	KRAS Ubiquitination at Lysine 104 Retains Exchange Factor Regulation by Dynamically Modulating the Conformation of the Interface. IScience, 2020, 23, 101448.	1.9	14
583	Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of YAP1. Journal of Biological Chemistry, 2020, 295, 13965-13980.	1.6	8
584	Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma. Medicine (United States), 2020, 99, e21478.	0.4	10
585	Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer. Nature Communications, 2020, 11, 3701.	5.8	128
586	AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. Cell Communication and Signaling, 2020, 18, 115.	2.7	17
587	Ubiquitinâ€binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB Journal, 2020, 34, 12024-12039.	0.2	10
588	A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19435-19445.	3.3	9
589	Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 2020, 19, 1784-1796.	1.9	72
590	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	2.9	69
591	Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models. Frontiers in Oncology, 2020, 10, 1326.	1.3	14
592	A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer. Molecular and Cellular Oncology, 2020, 7, 1791671.	0.3	3
593	Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?. Biomedicines, 2020, 8, 281.	1.4	26
594	KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2Kâ€“MAPK1 inhibition. Journal of Experimental Medicine, 2020, 217, .	4.2	10
595	Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. Scientific Reports, 2020, 10, 17455.	1.6	1
596	Targeting KRAS-Mutant Nonâ€“Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of Clinical Oncology, 2020, 38, 4208-4218.	0.8	30
597	Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS. Cell Reports, 2020, 32, 108074.	2.9	26

#	Article	IF	Citations
598	Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications, 2020, 11, 5439.	5.8	188
599	Post-translational modification of KRAS: potential targets for cancer therapy. Acta Pharmacologica Sinica, 2021, 42, 1201-1211.	2.8	21
600	The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Journal of Hematology and Oncology, 2020, 13, 113.	6.9	232
601	Multifaceted Roles of Heat Shock Factor 1 (HSF 1) in Cancer. Heat Shock Proteins, 2020, , 101-116.	0.2	0
602	Targeting RNA helicase DHX33 blocks Rasâ€driven lung tumorigenesis in vivo. Cancer Science, 2020, 111, 3564-3575.	1.7	10
603	Recent advances in the development of proteinâ€“protein interactions modulators: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2020, 5, 213.	7.1	387
604	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm, 2020, 1, 121-128.	3.1	16
605	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	13.9	1,049
606	RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?. Critical Reviews in Biochemistry and Molecular Biology, 2020, 55, 386-407.	2.3	27
607	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	1.7	171
608	Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. Journal of Clinical Medicine, 2020, 9, 2852.	1.0	39
609	NMR in integrated biophysical drug discovery for RAS: past, present, and future. Journal of Biomolecular NMR, 2020, 74, 531-554.	1.6	9
610	Structural impact of GTP binding on downstream KRAS signaling. Chemical Science, 2020, 11, 9272-9289.	3.7	25
611	Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Research, 2021, 81, 199-212.	0.4	20
612	PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells. Journal of Biological Chemistry, 2020, 295, 18343-18354.	1.6	11
613	Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases. CardioVascular and Interventional Radiology, 2020, 43, 1006-1014.	0.9	12
614	Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review. Advances in Therapy, 2020, 37, 2580-2603.	1.3	27
615	Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nature Communications, 2020, 11, 1800.	5.8	25

#	Article	IF	Citations
616	KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Medicinal Chemistry, 2020, 11, 760-770.	1.7	95
617	Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. Journal of Biological Chemistry, 2020, 295, 9948-9958.	1.6	7
618	The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer. Cancers, 2020, 12, 1382.	1.7	10
619	Efficient Gene Therapy of Pancreatic Cancer via a Peptide Nucleic Acid (PNA)â€Loaded Layered Double Hydroxides (LDH) Nanoplatform. Small, 2020, 16, e1907233.	5.2	34
620	RAC1mutation is not a predictive biomarker for PI3â€™â€kinaseâ€Î²â€selective pathwayâ€targeted therapy. Pigment Cell and Melanoma Research, 2020, 33, 719-730.	1.5	2
621	Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127290.	1.0	1
622	Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sciences, 2020, 255, 117816.	2.0	18
623	Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells. Signal Transduction and Targeted Therapy, 2020, 5, 83.	7.1	4
624	High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12826-12835.	3.3	68
625	Structure of two G-quadruplexes in equilibrium in the KRAS promoter. Nucleic Acids Research, 2020, 48, 9336-9345.	6.5	42
626	The Application of Ferroptosis in Diseases. Pharmacological Research, 2020, 159, 104919.	3.1	236
627	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Medicine, 2020, 12, 47.	3.6	107
628	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552.	21.5	569
629	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. Oncogenesis, 2020, 9, 59.	2.1	6
630	ARF family GTPases with links to cilia. American Journal of Physiology - Cell Physiology, 2020, 319, C404-C418.	2.1	29
632	Proteome-wide Interrogation of Small GTPases Regulated by N⁶-Methyladenosine Modulators. Analytical Chemistry, 2020, 92, 10145-10152.	3.2	9
633	A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants. Cancers, 2020, 12, 1412.	1.7	10
634	HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma. Cancer Research, 2020, 80, 3265-3278.	0.4	30

#	Article	IF	Citations
635	Current therapy of KRAS-mutant lung cancer. Cancer and Metastasis Reviews, 2020, 39, 1159-1177.	2.7	66
636	Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. International Journal of Molecular Sciences, 2020, 21, 4325.	1.8	84
637	Glycogen Synthase Kinase 3Î² in Cancer Biology and Treatment. Cells, 2020, 9, 1388.	1.8	46
638	RalB degradation by dihydroartemisinin induces autophagy and IFI16/caspase-1 inflammasome depression in the human laryngeal squamous cell carcinoma. Chinese Medicine, 2020, 15, 64.	1.6	10
639	Cancer vaccines: Targeting KRAS-driven cancers. Expert Review of Vaccines, 2020, 19, 163-173.	2.0	30
640	Targeting Kras^{g12c}â€mutant cancer with a mutationâ€specific inhibitor. Journal of Internal Medicine, 2020, 288, 183-191.	2.7	56
641	Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy. Journal of Controlled Release, 2020, 322, 236-247.	4.8	83
642	RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Science Signaling, 2020, 13, .	1.6	62
643	Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance. European Journal of Medicinal Chemistry, 2020, 194, 112269.	2.6	18
644	Two Distinct Structures of Membraneâ€Associated Homodimers of GTPâ€•and GDPâ€Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement. Angewandte Chemie - International Edition, 2020, 59, 11037-11045.	7.2	62
645	Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCÎµ/PKCÎµ Signaling Pathway. Frontiers in Oncology, 2020, 10, 75.	1.3	1
646	Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy. Frontiers in Pharmacology, 2020, 11, 280.	1.6	24
647	The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. Frontiers in Genetics, 2020, 11, 17.	1.1	7
648	How to make an undruggable enzyme druggable: lessons from ras proteins. Advances in Protein Chemistry and Structural Biology, 2020, 122, 181-202.	1.0	3
649	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de CancÃ©rologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. JTO Clinical and Research Reports, 2020, 1, 100052.	0.6	9
650	miR193b Promotes Apoptosis of Gastric Cancer Cells via Directly Mediating the Akt Pathway. BioMed Research International, 2020, 2020, 1-11.	0.9	4
651	Discovery of Novel PDEÎ´ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. Journal of Medicinal Chemistry, 2020, 63, 7892-7905.	2.9	43
652	Covalent inhibitors: a rational approach to drug discovery. RSC Medicinal Chemistry, 2020, 11, 876-884.	1.7	187

#	Article	IF	Citations
653	Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe. Cell Death and Disease, 2020, 11, 499.	2.7	4
654	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma HarboringHRASMutations. Clinical Cancer Research, 2020, 26, 5113-5119.	3.2	27
655	Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia, 2020, 22, 365-375.	2.3	7
656	Beta 1 integrin signaling mediates pancreatic ductal adenocarcinoma resistance to MEK inhibition. Scientific Reports, 2020, 10, 11133.	1.6	11
657	Genome-wide DNA methylation analysis of KRAS mutant cell lines. Scientific Reports, 2020, 10, 10149.	1.6	7
658	A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. Nature Communications, 2020, 11, 3233.	5.8	68
659	Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 647-661.	1.1	46
660	Biology, pathology, and therapeutic targeting of RAS. Advances in Cancer Research, 2020, 148, 69-146.	1.9	17
661	An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16938-16948.	3.3	26
662	Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases. Frontiers in Genetics, 2020, 11, 96.	1.1	18
663	Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS^{G12C} and ARS compounds. Organic and Biomolecular Chemistry, 2020, 18, 3069-3081.	1.5	16
664	Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids. Journal of Biological Chemistry, 2020, 295, 4526-4540.	1.6	19
665	Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutantâ€“driven tumor growth. Science Advances, 2020, 6, eaay2174.	4.7	51
666	KRAS: Structure, function, and development of anticancer drugs. , 2020, , 359-389.		0
667	KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. Cancer Treatment Reviews, 2020, 84, 101974.	3.4	143
668	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9
669	Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells, 2020, 9, 198.	1.8	314
670	KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells, 2020, 9, 219.	1.8	46

#	Article	IF	Citations
671	Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy. Future Science OA, 2020, 6, FSO455.	0.9	3
672	The Emerging Role of the Mammalian Glycocalyx in Functional Membrane Organization and Immune System Regulation. Frontiers in Cell and Developmental Biology, 2020, 8, 253.	1.8	128
673	Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS^{G12C}. ChemMedChem, 2020, 15, 827-832.	1.6	20
674	Advances of single-cell genomics and epigenomics in human disease: where are we now?. Mammalian Genome, 2020, 31, 170-180.	1.0	9
675	Two Distinct Structures of Membraneâ€Associated Homodimers of GTPâ€•and GDPâ€Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement. Angewandte Chemie, 2020, 132, 11130-11138.	1.6	5
676	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 917-930.	1.1	29
677	Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127144.	1.0	7
678	Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics. Cell Reports, 2020, 30, 4584-4599.e4.	2.9	53
679	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open, 2020, 5, e000634.	2.0	20
680	Big data and artificial intelligence discover novel drugs targeting proteins without 3D structure and overcome the undruggable targets. Stroke and Vascular Neurology, 2020, 5, 381-387.	1.5	10
681	PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer. Toxicology and Applied Pharmacology, 2020, 398, 115019.	1.3	12
682	Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine. Clinical Cancer Research, 2020, 26, 3408-3419.	3.2	35
683	High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A Ï€-stacking interactions for small-molecule recognition. Nucleic Acids Research, 2020, 48, 5766-5776.	6.5	34
684	A novel terpenoid class for prevention and treatment of KRASâ€driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems. Molecular Carcinogenesis, 2020, 59, 886-896.	1.3	9
685	Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer. Biochemical Pharmacology, 2020, 177, 113960.	2.0	18
686	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
687	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clinical Lung Cancer, 2020, 21, 384-388.	1.1	11
688	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	1.9	15

#	Article	IF	Citations
689	miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. Molecular Cancer Research, 2020, 18, 311-323.	1.5	27
690	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treatment Reviews, 2020, 86, 101998.	3.4	25
691	Pathogenesis of bowel endometriosis. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 71, 2-13.	1.4	8
692	Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells. Small GTPases, 2021, 12, 67-78.	0.7	22
693	Structural diversity in de novo cyclic peptide ligands from genetically encoded library technologies. Peptide Science, 2021, 113, e24204.	1.0	9
694	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188461.	3.3	68
695	Therapeutics Targeting Mutant KRAS. Annual Review of Medicine, 2021, 72, 349-364.	5.0	41
696	Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles. Journal of Proteome Research, 2021, 20, 670-683.	1.8	12
697	Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clinical Cancer Research, 2021, 27, 342-354.	3.2	88
698	pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Molecular Pharmaceutics, 2021, 18, 87-100.	2.3	31
699	The RAL signaling network: Cancer and beyond. International Review of Cell and Molecular Biology, 2021, 361, 21-105.	1.6	11
700	Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors. European Journal of Medicinal Chemistry, 2021, 213, 113082.	2.6	14
701	The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1. Human Gene Therapy, 2021, 32, 138-149.	1.4	11
702	Revealing the anticancer potential of candidate drugs in vivo using Caenorhabditis elegans mutant strains. Translational Oncology, 2021, 14, 100940.	1.7	7
703	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Cancer Letters, 2021, 499, 265-278.	3.2	16
704	A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. Pharmacological Research, 2021, 164, 105304.	3.1	17
705	Validated HPLCâ€MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice. Biomedical Chromatography, 2021, 35, e5043.	0.8	11
706	Discoveries in the redox regulation of KRAS. International Journal of Biochemistry and Cell Biology, 2021, 131, 105901.	1.2	2

#	Article	IF	Citations
707	Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22674.	1.4	25
708	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. Biochemical and Biophysical Research Communications, 2021, 534, 1-7.	1.0	2
709	How wide is the application of genetic big data in biomedicine. Biomedicine and Pharmacotherapy, 2021, 133, 111074.	2.5	5
710	Drug design targeting active posttranslational modification protein isoforms. Medicinal Research Reviews, 2021, 41, 1701-1750.	5.0	33
712	BI-3406, a Potent and Selective SOS1â€“KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery, 2021, 11, 142-157.	7.7	223
713	Approaches to inhibiting oncogenic K-Ras. Small GTPases, 2021, 12, 96-105.	0.7	29
714	Query-guided proteinâ€“protein interaction inhibitor discovery. Chemical Science, 2021, 12, 4753-4762.	3.7	5
715	Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Cancer Cell International, 2021, 21, 49.	1.8	5
716	Regulation of ARL2 in colorectal cancer cell proliferation and tumorigenicity, and its negative association with AXL. Oncology Letters, 2021, 21, 196.	0.8	1
717	G-proteins | Ras Family. , 2021, , 479-487.		0
718	Bioreducible, arginine-rich polydisulfide-based siRNA nanocomplexes with excellent tumor penetration for efficient gene silencing. Biomaterials Science, 2021, 9, 5275-5292.	2.6	10
719	Validation of Isoform- and Mutation-Specific RAS Antibodies. Methods in Molecular Biology, 2021, 2262, 91-103.	0.4	2
720	Binding Mode Prediction and Virtual Screening Applications by Covalent Docking. Methods in Molecular Biology, 2021, 2266, 73-88.	0.4	3
721	Mechanisms of Resistance to KRASG12C Inhibitors. Cancers, 2021, 13, 151.	1.7	81
722	Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. Scientific Reports, 2021, 11, 1712.	1.6	6
723	Understanding Ras Spatial Cycles Through Reaction-Diffusion Simulations. Methods in Molecular Biology, 2021, 2262, 199-215.	0.4	0
724	Photo-induced radical thiolâ€“ene chemistry: a versatile toolbox for peptide-based drug design. Chemical Society Reviews, 2021, 50, 898-944.	18.7	36
726	KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	32

#	Article	IF	Citations
727	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Investigational New Drugs, 2021, 39, 821-828.	1.2	24
728	Chemical Approach Toward Controlling of Transient Protein Interactions. , 2021, , 77-96.		0
729	Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer. International Journal of Biological Sciences, 2021, 17, 3634-3645.	2.6	5
730	Super-Resolution Imaging and Spatial Analysis of RAS on Intact Plasma Membrane Sheets. Methods in Molecular Biology, 2021, 2262, 217-232.	0.4	5
731	Liquid droplets of protein LAF1 provide a vehicle to regulate storage of the signaling protein K-Ras4B and its transport to the lipid membrane. Physical Chemistry Chemical Physics, 2021, 23, 5370-5375.	1.3	5
732	Co-overexpression of RIOK1 and AKT1 as a prognostic risk factor in glioma. Journal of Cancer, 2021, 12, 5745-5752.	1.2	4
733	Ras Signaling in Breast Cancer. Advances in Experimental Medicine and Biology, 2021, 1187, 81-101.	0.8	7
734	Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins. Computational and Structural Biotechnology Journal, 2021, 19, 1184-1199.	1.9	51
735	Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective. Frontiers in Chemistry, 2020, 8, 612728.	1.8	19
736	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
737	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 2021, 5, 1900236.	1.4	13
738	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	0.8	7
739	Inhibition of Nonfunctional Ras. Cell Chemical Biology, 2021, 28, 121-133.	2.5	23
740	KRAS mutation in pancreatic cancer. Seminars in Oncology, 2021, 48, 10-18.	0.8	95
741	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacology and Translational Science, 2021, 4, 703-712.	2.5	7
742	Recent Developments in Small-Molecule Ligands of Medicinal Relevance for Harnessing the Anticancer Potential of G-Quadruplexes. Molecules, 2021, 26, 841.	1.7	38
743	RAS Amplification as a Negative Predictor of Benefit from Anti-EGFRâ€“Containing Therapy Regimens in Metastatic Colorectal Cancer. Oncologist, 2021, 26, 469-475.	1.9	7
744	Interaction between RAS gene and lipid metabolism in cancer. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2021, 50, 17-22.	0.1	1

#	Article	IF	Citations
746	The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochemical Society Transactions, 2021, 49, 253-267.	1.6	29
747	The KRAS and other prenylated polybasic domain membrane anchors recognize phosphatidylserine acyl chain structure. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
748	Targeting KRAS in Colorectal Cancer. Current Oncology Reports, 2021, 23, 28.	1.8	24
749	Autophagy buffers Ras-induced genotoxic stress enabling malignant transformation in keratinocytes primed by human papillomavirus. Cell Death and Disease, 2021, 12, 194.	2.7	7
750	Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation. OncoTargets and Therapy, 2021, Volume 14, 1113-1116.	1.0	2
751	Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators. Acta Pharmaceutica Sinica B, 2021, 11, 3433-3446.	5.7	20
753	The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Frontiers in Oncology, 2021, 11, 626971.	1.3	64
754	Differential Outcomes in Codon 12/13 and Codon 61NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients withNRAS-Mutated Tumors. Clinical Cancer Research, 2021, 27, 2996-3004.	3.2	23
755	Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder. Molecular Biology Reports, 2021, 48, 2183-2199.	1.0	4
756	The metabolic landscape of RAS-driven cancers from biology to therapy. Nature Cancer, 2021, 2, 271-283.	5.7	139
757	Molecular Oncology in Management of Colorectal Cancer. Indian Journal of Surgical Oncology, 2021, 12, 169-180.	0.3	0
758	Targeting â€œundruggableâ€•c-Myc protein by synthetic lethality. Frontiers of Medicine, 2021, 15, 541-550.	1.5	8
759	Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. Communications Biology, 2021, 4, 374.	2.0	11
760	Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology. Oncotarget, 2021, 12, 422-439.	0.8	13
761	Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	39
762	An expanded universe of cancer targets. Cell, 2021, 184, 1142-1155.	13.5	135
763	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.	1.3	42
764	A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Molecular and Cellular Biology, 2021, 41, .	1.1	15

#	Article	IF	Citations
765	Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
766	Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. BMC Cancer, 2021, 21, 237.	1.1	14
767	Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discovery, 2021, 11, 1345-1352.	7.7	60
768	Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Cells, 2021, 10, 985.	1.8	7
769	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics, 2021, 4, 2000262.	1.6	9
770	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer, 2021, 154, 161-175.	0.9	105
771	Suppression of Wnt/Î²-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer. Biochemical and Biophysical Research Communications, 2021, 549, 40-46.	1.0	18
772	PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis. Molecular Cell, 2021, 81, 1698-1714.e6.	4.5	35
773	Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers, 2021, 13, 1928.	1.7	14
775	Regulation of Dynamic Protein S-Acylation. Frontiers in Molecular Biosciences, 2021, 8, 656440.	1.6	19
776	KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 154, 51-61.	0.9	43
777	RGL2 Drives the Metastatic Progression of Colorectal Cancer via Preventing the Protein Degradation of Î²-Catenin and KRAS. Cancers, 2021, 13, 1763.	1.7	6
778	Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress. JCI Insight, 2021, 6, .	2.3	2
779	ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nature Chemical Biology, 2021, 17, 856-864.	3.9	49
780	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4012-4024.	3.2	20
781	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open, 2021, 6, 100040.	2.0	19
783	TheÂlatest developments in the field of therapeutic delivery, December 2020. Therapeutic Delivery, 2021, 12, 271-285.	1.2	3
784	The importance of Ras in drug resistance in cancer. British Journal of Pharmacology, 2022, 179, 2844-2867.	2.7	26

#	Article	IF	Citations
785	The Role of Wild-Type RAS in Oncogenic RAS Transformation. Genes, 2021, 12, 662.	1.0	21
786	Comprehensive Clinical and Molecular Characterization of KRAS^{G12C}-Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	1.5	31
787	An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy. Communications Biology, 2021, 4, 452.	2.0	15
788	Understand KRAS and the Quest for Anti-Cancer Drugs. Cells, 2021, 10, 842.	1.8	10
789	Ras sumoylation in cell signaling and transformation. Seminars in Cancer Biology, 2021, 76, 301-309.	4.3	11
790	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Medicinal Chemistry Letters, 2021, 12, 791-797.	1.3	3
791	Emerging Trends in Cancer Drug Discoveryâ€"From Drugging the â€œUndruggableâ€• to Overcoming Resistance. Cancer Discovery, 2021, 11, 815-821.	7.7	24
792	Precision oncology in metastatic colorectal cancer â€" from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	12.5	113
793	Misshapen Disruption Cooperates with RasV12 to Drive Tumorigenesis. Cells, 2021, 10, 894.	1.8	1
794	Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduction and Targeted Therapy, 2021, 6, 144.	7.1	37
795	Searching for treatments for non-G12C-KRAS mutant cancers. British Journal of Cancer, 2021, 125, 625-626.	2.9	4
796	Role of stromal activin A in human pancreatic cancer and metastasis in mice. Scientific Reports, 2021, 11, 7986.	1.6	16
797	Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS ONE, 2021, 16, e0252314.	1.1	3
798	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines, 2021, 9, 509.	2.1	14
799	AGO2 promotes tumor progression in KRAS-driven mouse models of nonâ€"small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
800	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 2021, 13, 653.	2.0	33
801	Sequenceâ€Selective Covalent CaaXâ€Box Receptors Prevent Farnesylation of Oncogenic Ras Proteins and Impact MAPK/PI3â€…K Signaling. ChemMedChem, 2021, 16, 2504-2514.	1.6	3
802	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications, 2021, 12, 2606.	5.8	41

#	Article	IF	Citations
803	Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. European Journal of Medicinal Chemistry, 2021, 217, 113381.	2.6	7
804	Focused Libraries for Epigenetic Drug Discovery: The Importance of Isosteres. Journal of Medicinal Chemistry, 2021, 64, 7231-7240.	2.9	12
805	KRAS G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	1.2	40
806	KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection. Journal of Clinical Practice, 2021, 12, 66-71.	0.2	1
807	Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. European Journal of Cancer, 2021, 149, 184-192.	1.3	4
808	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.1	0
809	KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. Frontiers in Oncology, 2021, 11, 672612.	1.3	38
810	KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Cancers, 2021, 13, 2429.	1.7	18
811	40 Years of RASâ€”A Historic Overview. Genes, 2021, 12, 681.	1.0	24
812	Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. Bioorganic Chemistry, 2021, 110, 104825.	2.0	12
813	Targeting the KRAS Î±4-Î±5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases, 2021, , 1-14.	0.7	11
814	Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nature Communications, 2021, 12, 2656.	5.8	51
815	Ligand decorated biodegradable nanomedicine in the treatment of cancer. Pharmacological Research, 2021, 167, 105544.	3.1	14
816	BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer. Molecular and Cellular Biochemistry, 2021, 476, 3469-3482.	1.4	4
817	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 201.	7.1	607
818	Ras Isoforms from Lab Benches to Livesâ€”What Are We Missing and How Far Are We?. International Journal of Molecular Sciences, 2021, 22, 6508.	1.8	5
819	Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling. Current Medicinal Chemistry, 2021, 28, 3476-3489.	1.2	2
821	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Reports, 2021, 35, 109291.	2.9	15

#	Article	IF	Citations
822	Antipsychotic phenothiazine drugs bind to KRAS in vitro. Journal of Biomolecular NMR, 2021, 75, 233-244.	1.6	2
823	Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity. Frontiers in Molecular Biosciences, 2021, 8, 673096.	1.6	9
824	Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine, 2021, 384, 2371-2381.	13.9	833
825	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Blood, 2021, 138, 1705-1720.	0.6	10
826	Industry update: the latest developments in the field of therapeutic delivery, February 2021. Therapeutic Delivery, 2021, 12, 427-442.	1.2	0
827	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1174, 122718.	1.2	11
829	KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor. Journal of Gastrointestinal Oncology, 2021, 12, 1020-1030.	0.6	1
830	Targeting mutant KRAS. Current Opinion in Chemical Biology, 2021, 62, 101-108.	2.8	16
831	Microarrays and NGS for Drug Discovery. , 0, , .		0
832	RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains. Frontiers in Molecular Biosciences, 2021, 8, 686338.	1.6	12
833	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Research, 2021, 81, 4054-4065.	0.4	24
834	Conformational Features of Ras: Key Hydrogen-Bonding Interactions of Gln61 in the Intermediate State during GTP Hydrolysis. Journal of Physical Chemistry B, 2021, 125, 8805-8813.	1.2	12
835	Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nature Reviews Cancer, 2021, 21, 510-525.	12.8	102
837	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications, 2021, 12, 4365.	5.8	53
839	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist, 2021, 26, 845-853.	1.9	26
840	Harnessing Carcinoma Cell Plasticity Mediated by TGF-Î² Signaling. Cancers, 2021, 13, 3397.	1.7	9
841	Ras isoform-specific expression, chromatin accessibility, and signaling. Biophysical Reviews, 2021, 13, 489-505.	1.5	14
842	Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors. Cell Systems, 2021, 12, 716-732.e7.	2.9	9

#	Article	IF	Citations
843	Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. , 2021, 9, e002474.		34
844	Anthraquinones as Inhibitors of SOS RAS-GEF Activity. Biomolecules, 2021, 11, 1128.	1.8	4
845	Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. Expert Opinion on Therapeutic Patents, 2021, 31, 1189-1204.	2.4	14
846	Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Molecular Pharmaceutics, 2021, 18, 3509-3518.	2.3	2
847	Lung cancer. Lancet, The, 2021, 398, 535-554.	6.3	896
848	Panâ€'RAF inhibitor LY3009120 is highly synergistic with lowâ€'dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncology Letters, 2021, 22, 745.	0.8	5
849	Predicting and characterizing a cancer dependency map of tumors with deep learning. Science Advances, 2021, 7, .	4.7	29
850	Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies. Biological Research, 2021, 54, 23.	1.5	17
851	Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Nature Communications, 2021, 12, 4688.	5.8	7
852	KRAS Inhibitor Resistance in MET-Amplified KRASG12C Nonâ€"Small Cell Lung Cancer Induced By RAS- and Nonâ€"RAS-Mediated Cell Signaling Mechanisms. Clinical Cancer Research, 2021, 27, 5697-5707.	3.2	42
853	The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. Cancers, 2021, 13, 4144.	1.7	7
854	Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience. Journal of Thoracic Disease, 2021, 13, 4785-4796.	0.6	1
855	A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular Cell, 2021, 81, 4076-4090.e8.	4.5	31
856	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS â€mutant cancer. EMBO Molecular Medicine, 2021, 13, e13193.	3.3	11
857	Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Review of Anticancer Therapy, 2021, 21, 1253-1264.	1.1	0
859	Rigosertib elicits potent anti-tumor responses in colorectal cancer by inhibiting Ras signaling pathway. Cellular Signalling, 2021, 85, 110069.	1.7	9
860	RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines. Scientific Reports, 2021, 11, 17925.	1.6	6
861	GSK3Î² as a novel promising target to overcome chemoresistance in pancreatic cancer. Drug Resistance Updates, 2021, 58, 100779.	6.5	45

#	Article	IF	Citations
862	NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 2021, 99, 102238.	3.4	56
863	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight, 2021, 6, .	2.3	12
864	Parallel Rap1>RalGEF>Ral and Ras signals sculpt the C.Âelegans nervous system. Developmental Biology, 2021, 477, 37-48.	0.9	0
865	Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. Genes and Diseases, 2023, 10, 403-414.	1.5	5
866	Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 2021, 22, 10219.	1.8	14
868	KRAS G12C fragment screening renders new binding pockets. Small GTPases, 2022, 13, 225-238.	0.7	9
869	Lipid Profiles of RAS Nanoclusters Regulate RAS Function. Biomolecules, 2021, 11, 1439.	1.8	13
870	Molecular Approach to Colorectal Carcinoma. Surgical Pathology Clinics, 2021, 14, 429-441.	0.7	4
871	Inhibitory activity of acteoside in melanoma via regulation of the ERÎ²-Ras/Raf1-STAT3 pathway. Archives of Biochemistry and Biophysics, 2021, 710, 108978.	1.4	9
872	On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer, 2021, 160, 152-165.	0.9	24
873	Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine. Phytomedicine, 2021, 91, 153718.	2.3	5
874	Targeting mutated GTPase KRAS in tumor therapies. European Journal of Medicinal Chemistry, 2021, 226, 113816.	2.6	19
875	Signaling in the crowded cell. Current Opinion in Structural Biology, 2021, 71, 43-50.	2.6	8
876	The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations. Current Opinion in Structural Biology, 2021, 71, 164-170.	2.6	8
877	KRAS: The Art of Understanding a Complex Gene. , 2022, , 876-888.		0
878	Epidemiology of oral cancer and its relationship with inflammation. , 2022, , 1-18.		0
879	Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients. Bioengineered, 2021, 12, 5099-5109.	1.4	2
880	Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. Theranostics, 2021, 11, 3472-3488.	4.6	6

#	Article	IF	Citations
881	Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients. Journal of Translational Medicine, 2021, 19, 27.	1.8	43
882	Implications of Peak Selection in the Interpretation of Unsupervised Mass Spectrometry Imaging Data Analyses. Analytical Chemistry, 2021, 93, 2309-2316.	3.2	18
883	Emerging RAS-directed therapies for cancer. , 2021, 4, 543-558.		8
884	Ras and Ras Signaling as a Therapeutic Target in Cancer. , 2021, , .		0
885	Design and Synthesis of Tetrahydroisoquinoline Derivatives as AntiAngiogenesis and Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	0
886	Research on HOXA11-AS in Malignant Tumors. Journal of Cancer Therapy, 2021, 12, 19-30.	0.1	0
887	Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. Methods in Molecular Biology, 2017, 1636, 485-506.	0.4	11
888	Vaccine Therapy in Pancreatic Cancer. , 2018, , 281-307.		1
890	Posttranslational Modifications of Small G Proteins. , 2014, , 99-131.		5
891	Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein and Cell, 2021, 12, 599-620.	4.8	837
892	The Multiple Myeloma Drug Pipelineâ€"2018: AÂReview of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 611-627.	0.2	45
893	Overcoming Resistance to Drugs Targeting KRAS Mutation. Innovation(China), 2020, 1, 100035.	5.2	44
894	Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells. ACS Applied Bio Materials, 2020, 3, 8481-8495.	2.3	4
895	Translating current basic research into future therapies for neurofibromatosis type 1. British Journal of Cancer, 2020, 123, 178-186.	2.9	17
896	RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochemical Journal, 2020, 477, 2893-2919.	1.7	12
897	Inhibition of RAS: proven and potential vulnerabilities. Biochemical Society Transactions, 2020, 48, 1831-1841.	1.6	15
898	Scratching the surface: native mass spectrometry of peripheral membrane protein complexes. Biochemical Society Transactions, 2020, 48, 547-558.	1.6	20
908	Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. Cancer Science, 2020, 111, 1076-1083.	1.7	12

#	Article	IF	Citations
909	Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight, 2018, 3, .	2.3	24
910	Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Journal of Clinical Investigation, 2020, 130, 1752-1766.	3.9	200
911	Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. F1000Research, 2019, 8, 849.	0.8	50
912	A â€˜synthetic-sicknessâ€™ screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genetics, 2017, 13, e1006942.	1.5	9
913	Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PLoS ONE, 2015, 10, e0126891.	1.1	41
914	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 2016, 11, e0147682.	1.1	32
915	Identification of Binding Targets of a Pyrrole-Imidazole Polyamide KR12 in the LS180 Colorectal Cancer Genome. PLoS ONE, 2016, 11, e0165581.	1.1	11
916	Multiple components of PKA and TGF-Î² pathways are mutated in pseudomyxoma peritonei. PLoS ONE, 2017, 12, e0174898.	1.1	15
917	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	0.8	47
918	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. Oncotarget, 2016, 7, 50490-50506.	0.8	21
919	RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget, 2016, 7, 65147-65156.	0.8	7
920	SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget, 2016, 7, 80336-80349.	0.8	35
921	Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget, 2016, 7, 86948-86971.	0.8	23
922	Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling. Oncotarget, 2017, 8, 28359-28372.	0.8	20
923	A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 24250-24261.	0.8	8
924	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	0.8	5
925	BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. Oncotarget, 2017, 8, 44669-44681.	0.8	21
926	STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget, 2017, 8, 78556-78572.	0.8	8

#	Article	IF	Citations
927	BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget, 2018, 9, 18734-18746.	0.8	12
928	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget, 2018, 9, 33995-34008.	0.8	9
929	A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells. Oncotarget, 2018, 9, 34379-34397.	0.8	11
930	Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia. Oncotarget, 2019, 10, 1932-1942.	0.8	4
931	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. Oncotarget, 2019, 10, 4761-4775.	0.8	45
932	A bacterial toxin that cleaves Ras oncoprotein. Oncotarget, 2015, 6, 18742-18743.	0.8	4
933	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget, 2015, 6, 32368-32379.	0.8	25
934	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget, 2017, 8, 13611-13619.	0.8	81
935	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. Oncotarget, 2016, 7, 52597-52612.	0.8	45
936	Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget, 2016, 7, 51462-51472.	0.8	21
937	Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules. Current Medicinal Chemistry, 2018, 24, 4873-4904.	1.2	29
938	The Function of RAS Mutation in Cancer and Advances in its Drug Research. Current Pharmaceutical Design, 2019, 25, 1105-1114.	0.9	53
939	Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. Current Topics in Medicinal Chemistry, 2019, 19, 2114-2127.	1.0	4
940	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2128-2142.	1.0	9
941	Targeting Mutant KRAS for Anticancer Therapy. Current Topics in Medicinal Chemistry, 2019, 19, 2098-2113.	1.0	12
942	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2158-2175.	1.0	4
943	KRAS: A Promising Therapeutic Target for Cancer Treatment. Current Topics in Medicinal Chemistry, 2019, 19, 2081-2097.	1.0	29
944	Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1540-1550.	0.9	7

#	Article	IF	Citations
945	Membrane curvature sensing of the lipid-anchored K-Ras small GTPase. Life Science Alliance, 2019, 2, e201900343.	1.3	35
946	Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function. Life Science Alliance, 2019, 2, e201900431.	1.3	29
947	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Annals of Breast Cancer and Therapy, 2020, 4, 48-57.	0.8	11
948	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
949	p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World Journal of Gastroenterology, 2018, 24, 3709-3723.	1.4	33
950	Prognostic Role of KRAS mRNA Expression in Breast Cancer. Journal of Breast Cancer, 2019, 22, 548.	0.8	20
951	Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect. Journal of Oral and Maxillofacial Pathology, 2018, 22, 65.	0.3	15
952	Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression. Cancer Research and Treatment, 2020, 52, 1067-1083.	1.3	3
953	Mutational analysis of Ras hotspots in patients with urothelial carcinoma of the bladder. World Journal of Clinical Oncology, 2020, 11, 614-628.	0.9	5
954	Structure, signaling and the drug discovery of the Ras oncogene protein. BMB Reports, 2017, 50, 355-360.	1.1	18
955	Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation. ELife, 2015, 4, e08905.	2.8	45
956	One reporter for in-cell activity profiling of majority of protein kinase oncogenes. ELife, 2017, 6, .	2.8	12
957	SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. ELife, 2017, 6, .	2.8	70
958	RalB directly triggers invasion downstream Ras by mobilizing the Wave complex. ELife, 2018, 7, .	2.8	27
959	Protein phase separation and its role in tumorigenesis. ELife, 2020, 9, .	2.8	63
960	Targeted Therapy. UNIPA Springer Series, 2021, , 181-206.	0.1	0
961	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Molecular Cancer, 2021, 20, 128.	7.9	41
962	Targeting small GTPases and their downstream pathways with intracellular macromolecule binders to define alternative therapeutic strategies in cancer. Biochemical Society Transactions, 2021, 49, 2021-2035.	1.6	0

#	Article	IF	Citations
963	Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. Frontiers in Oncology, 2021, 11, 741326.	1.3	15
964	DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Rasâ€“ERK pathway. Journal of Biochemistry, 2022, 171, 109-122.	0.9	5
966	Mechanism of activation and the rewired network: New drug design concepts. Medicinal Research Reviews, 2022, 42, 770-799.	5.0	15
967	Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 2021, 40, 6759-6771.	2.6	13
968	Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers, 2021, 13, 5081.	1.7	13
969	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 2021, 13, 5059.	1.7	39
970	Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC). Oral Oncology, 2021, 122, 105546.	0.8	4
971	Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity. Bioorganic Chemistry, 2021, 117, 105447.	2.0	15
972	Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D. Computers in Biology and Medicine, 2021, 139, 104946.	3.9	15
973	KRAS Cold Turkey: Using microRNAs to target KRAS-addicted cancer. RNA & Disease (Houston, Tex), 2015, 2, .	1.0	1
974	RAS Transformation Targets. , 2015, , 1-5.		0
975	MicroRNA Therapeutics: Basic Principles, Barriers and Perspectives. , 2015, 1, 1-5.		1
976	Rap GEF Family. , 2016, , 1-8.		0
977	Rho Family Proteins. , 2016, , 4076-4082.		0
978	RAS Transformation Targets. , 2016, , 3922-3927.		0
979	The second annual conference of International ovarian cancer consortium and the symposium on tumor microenvironment and therapeutic resistance. Genes and Cancer, 2016, 7, 7-12.	0.6	0
980	Metabolism in Pancreatic Cancer. , 2017, , 1-22.		0
981	Targeted Therapy and Precision Medicine. , 2017, , 183-200.		1

#	Article	IF	Citations
982	Molecular Genetics of Thyroid Cancer. , 2017, , 15-27.		0
985	Adverse effects of farnesyltransferase inhibitors on insulin actions. Journal of Biomedical Translational Research, 2017, 18, 113-117.	0.1	0
987	Precision Medicine Based on Next Generation Sequencing and Master Controllers. , 2018, , 1-35.		0
988	Rap GEF Family. , 2018, , 4454-4462.		0
989	In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma. Anticancer Research, 2018, 38, 1967-1977.	0.5	2
992	Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?. Japanese Journal of Lung Cancer, 2018, 58, 953-958.	0.0	0
993	Real-Time NMR. , 2019, , 1-10.		0
994	Enhancing the Therapeutic Potential of Platinum-based Anticancer Agents by Incorporating Clinically Approved Drugs as Ligands. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 1-30.	0.8	1
995	KRAS as Potential Target in Colorectal Cancer Therapy. , 2019, , 389-424.		1
996	Protein Palmitoylation in Cancer. , 2019, , 51-87.		2
998	Ras-EfektÃ¶r EtkileÅŸimlerinin YapÄ±sal DetaylarÄ±nÄ±n AÃ§Ä±ÄŸa Ã‡Ä±karÄ±lmasÄ±. International Journal of Advances in Engineering and Pure Sciences, 2019, 31, 90-99.	0.2	0
1011	KRas4BG12C/D/PDE6Î´ Heterodimeric Molecular Complex: A Target Molecular Multicomplex for the Identification and Evaluation of Nontoxic Pharmacological Compounds for the Treatment of Pancreatic Cancer. , 0, , .		2
1013	PANCREATIC CANCER, CURRENT THERAPEUTIC APPROACHES AND POSSIBLE PROSPECTS. , 2020, 19, 18-28.	0.3	0
1015	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study. Translational Cancer Research, 2020, 9, 7562-7571.	0.4	0
1016	Proteinâ€“membrane interactions in small GTPase signalling and pharmacology: perspectives from Arf GTPases studies. Biochemical Society Transactions, 2020, 48, 2721-2728.	1.6	5
1017	Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. , 2022, , 207-230.		0
1018	Role of Specific Phytochemicals Against Gastrointestinal Malignancies. , 2020, , 1-33.		1
1019	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. Oncology & Hematology Review, 2020, 16, 36.	0.2	0

#	Article	IF	Citations
1020	Quadruplex nucleic acids in KRAS targeted-cancer therapy. Annual Reports in Medicinal Chemistry, 2020, 54, 325-359.	0.5	1
1022	Estimation of Dissociation Constant of ARS-1620 Complex with KRASG12C Protein by Molecular Modeling. Moscow University Chemistry Bulletin, 2020, 75, 72-76.	0.2	0
1024	Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer. Future Science OA, 2021, 7, FSO757.	0.9	1
1025	Vertical Inhibition of the RAFâ€“MEKâ€“ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression inH/NRASQ61XMutant Rhabdomyosarcoma. Molecular Cancer Therapeutics, 2022, 21, 170-183.	1.9	12
1026	Context Mattersâ€"Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	1.8	3
1027	Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2022, 12, a037812.	2.9	8
1028	Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1. Oncogene, 2022, 41, 280-292.	2.6	10
1029	Metadherin (MTDH) overexpression significantly correlates with advanced tumor grade and stages among colorectal cancer patients. Molecular Biology Reports, 2021, 48, 7999-8007.	1.0	2
1031	Oncogenes in high grade serous adenocarcinoma of the ovary. Genes and Cancer, 2020, 11, 122-136.	0.6	2
1032	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Yale Journal of Biology and Medicine, 2015, 88, 389-95.	0.2	3
1033	HMGB1 regulates erastin-induced ferroptosis via RAS-JNK/p38 signaling in HL-60/NRAS cells. American Journal of Cancer Research, 2019, 9, 730-739.	1.4	44
1035	The Dual Role of HMGB1 in Pancreatic Cancer. Journal of Pancreatology, 2018, 1, 19-24.	0.3	3
1036	Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX. American Journal of Translational Research (discontinued), 2021, 13, 7458-7474.	0.0	1
1037	Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors. Cancers, 2021, 13, 5757.	1.7	3
1038	Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. Npj Precision Oncology, 2021, 5, 98.	2.3	35
1040	Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 1-12.	1.4	5
1041	KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 2021, 6, 386.	7.1	255
1042	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Targeted Oncology, 2022, 17, 35-41.	1.7	3

#	Article	IF	Citations
1043	Brain Metastasis in a Young Patient: Consider the Rectum. Cureus, 2021, 13, e20055.	0.2	0
1044	Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. British Journal of Cancer, 2022, 126, 744-753.	2.9	7
1045	Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer. Oncogene, 2022, 41, 809-823.	2.6	5
1046	Designing a fluorescence padlock probe-based biosensor and colorimetric assay forÂtheÂdetection of G12D KRAS mutation. Biomarkers in Medicine, 2021, 15, 1741-1754.	0.6	2
1048	Mutant K-Ras Mediated Oxidative Stress in Pancreatic Cancer. , 2021, , 1-11.		0
1049	Predicting proteinâ€“membrane interfaces of peripheral membrane proteins using ensemble machine learning. Briefings in Bioinformatics, 2022, 23, .	3.2	21
1050	Targeting KRAS in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 792635.	1.3	17
1051	In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis. Computers in Biology and Medicine, 2022, 141, 105110.	3.9	4
1052	Biochemical characterization of the interaction between KRAS and Argonaute 2. Biochemistry and Biophysics Reports, 2022, 29, 101191.	0.7	5
1053	Targeting RAS in neuroblastoma: Is it possible?. , 2022, 236, 108054.		9
1054	Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia. , 2021, , .		0
1055	Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays. Nano Letters, 2022, 22, 1007-1016.	4.5	7
1056	KRAS mutationâ€independent downregulation of MAPK/PI3K signaling in colorectal cancer. Molecular Oncology, 2022, 16, 1171-1183.	2.1	6
1057	Hydrophobic Tagging-Induced Degradation of PDEÎ´ in Colon Cancer Cells. ACS Medicinal Chemistry Letters, 2022, 13, 298-303.	1.3	10
1058	Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain. Advances in Cancer Research, 2022, 153, 267-304.	1.9	2
1059	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	1.7	7
1060	KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery, 2022, 8, 5.	3.1	52
1061	The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Journal of Experimental and Clinical Cancer Research, 2022, 41, 27.	3.5	73

#	Article	IF	Citations
1062	Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 780655.	1.3	12
1063	BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma. Antioxidants, 2022, 11, 114.	2.2	3
1065	Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma. Current Molecular Pharmacology, 2022, 15, .	0.7	0
1066	Inhibitors of the GTPase KRAS^{G12C}in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 2022, 32, 475-505.	2.4	6
1067	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Visceral Medicine, 2022, 38, 20-29.	0.5	7
1068	Covalent Fragment Screening Identifies Rgl2 RalGEF Cysteine for Targeted Covalent Inhibition of Ral GTPase Activation. ChemMedChem, 2022, , e202100750.	1.6	5
1069	Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. Advances in Cancer Research, 2022, 153, 29-61.	1.9	14
1070	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone. Advances in Cancer Research, 2022, 153, 131-168.	1.9	4
1071	Inhibition of SHP2 as an approach to block RAS-driven cancers. Advances in Cancer Research, 2022, 153, 205-236.	1.9	7
1072	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Advances in Cancer Research, 2022, 153, 101-130.	1.9	8
1073	Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188677.	3.3	5
1074	Targeting RAS oncogenesis with SOS1 inhibitors. Advances in Cancer Research, 2022, 153, 169-203.	1.9	13
1075	Mutant K-Ras-Mediated Oxidative Stress in Pancreatic Cancer. , 2022, , 1443-1453.		0
1076	Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy. , 2022, 236, 108110.		4
1077	Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. Developmental Cell, 2022, 57, 310-328.e9.	3.1	6
1078	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports, 2022, 38, 110351.	2.9	18
1079	Membrane Composition and Raf[CRD]-Membrane Attachment Are Driving Forces for K-Ras4B Dimer Stability. Journal of Physical Chemistry B, 2022, 126, 1504-1519.	1.2	4
1080	T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy. Frontiers in Immunology, 2022, 13, 833017.	2.2	13

#	Article	IF	Citations
1081	Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharmaceutica Sinica B, 2022, 12, 3085-3102.	5.7	9
1082	Targeting KRAS in NSCLC: Old Failures and New Options for â€œNon-G12câ€•Patients. Cancers, 2021, 13, 6332.	1.7	10
1083	Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?. Central European Journal of Public Health, 2021, 29, 247-258.	0.4	0
1084	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. Frontiers in Oncology, 2021, 11, 792385.	1.3	1
1085	Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS^{G12D} Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 3123-3133.	2.9	243
1087	Investigating the NRAS 5' UTR as a Target for Small Molecules. SSRN Electronic Journal, 0, , .	0.4	0
1088	Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation. Computational and Structural Biotechnology Journal, 2022, 20, 1056-1067.	1.9	5
1089	Development and validation of a robust and sensitive HPLC-MS/MS method for the quantitation of MRTX849 in plasma and its application in pharmacokinetics. Analyst, The, 2022, 147, 1175-1180.	1.7	3
1090	Protease-controlled secretion and display of intercellular signals. Nature Communications, 2022, 13, 912.	5.8	14
1091	Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Frontiers in Oncology, 2022, 12, 796832.	1.3	34
1092	Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acidâ€‘based antisense: A potential new drug candidate for pancreatic cancer. Oncology Letters, 2022, 23, 130.	0.8	6
1093	Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc. Molecular Pharmaceutics, 2022, 19, 1104-1116.	2.3	6
1094	Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and Î²-TrCP in the ubiquitinâ€“proteasome pathway. Cell Communication and Signaling, 2022, 20, 34.	2.7	7
1095	G-quadruplex inducer/stabilizer pyridostatin targets SUB1 to promote cytotoxicity of a transplatinum complex. Nucleic Acids Research, 2022, 50, 3070-3082.	6.5	6
1096	Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2022, 10, 830208.	1.8	13
1097	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	3.3	12
1098	Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner. Cancers, 2022, 14, 1628.	1.7	9
1099	Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Frontiers in Endocrinology, 2022, 13, 864253.	1.5	17

#	Article	IF	Citations
1100	Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. Journal of Medicinal Chemistry, 2022, 65, 3923-3942.	2.9	36
1101	Conformations and binding pockets of <scp>HRas</scp> and its guanine nucleotide exchange factors complexes in the guanosine triphosphate exchange process. Journal of Computational Chemistry, 2022, 43, 906-916.	1.5	9
1102	Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Medicinal Research Reviews, 2022, 42, 1607-1660.	5.0	20
1103	Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. International Journal of Molecular Sciences, 2022, 23, 3706.	1.8	5
1104	Single agent VS-6766 or VS-6766 plus defactinib inKRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. Future Oncology, 2022, 18, 1907-1915.	1.1	11
1105	The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Science Signaling, 2022, 15, eabm4452.	1.6	11
1106	Landscape of KRAS^{G12C}, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. JCO Precision Oncology, 2022, 6, e2100245.	1.5	31
1107	Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?. International Journal of Molecular Sciences, 2022, 23, 3620.	1.8	11
1109	Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening. European Journal of Medicinal Chemistry, 2022, 233, 114243.	2.6	13
1110	Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats. Frontiers in Oncology, 2022, 12, 778035.	1.3	2
1111	Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect. Frontiers in Molecular Biosciences, 2022, 9, 860962.	1.6	10
1112	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research, 2022, 178, 106137.	3.1	4
1113	Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer. Journal of Controlled Release, 2022, 344, 26-38.	4.8	10
1115	The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews, 2022, 106, 102383.	3.4	25
1117	Targeting Mutated KRAS Genes to Treat Solid Tumours. Molecular Diagnosis and Therapy, 2022, 26, 39-49.	1.6	13
1118	Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2022, 46, 509-518.	2.1	2
1119	Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 787585.	1.3	20
1121	Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23

#	Article	IF	Citations
1122	RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Molecular Imaging and Biology, 2022, 24, 498-509.	1.3	4
1123	Alternative polyadenylation is a determinant of oncogenic Ras function. Science Advances, 2021, 7, eabh0562.	4.7	7
1124	Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway. Frontiers in Oncology, 2021, 11, 768022.	1.3	0
1125	The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. Translational Lung Cancer Research, 2022, 11, 213-223.	1.3	6
1126	Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects. Blood Cancer Journal, 2022, 12, 64.	2.8	3
1127	Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D. Journal of Cystic Fibrosis, 2022, 21, 950-958.	0.3	9
1128	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discovery, 2022, 12, 1500-1517.	7.7	49
1129	Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic <scp>d</scp>-Peptide for Dual-Targeting Therapy of Lung Cancer. Journal of the American Chemical Society, 2022, 144, 7117-7128.	6.6	19
1130	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. Frontiers in Pharmacology, 2022, 13, 875330.	1.6	4
1131	LRRK2 as a target for modulating immune system responses. Neurobiology of Disease, 2022, 169, 105724.	2.1	11
1136	Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene, 2022, 41, 2973-2983.	2.6	9
1137	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 762-774.	1.9	9
1139	Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. PLoS Computational Biology, 2022, 18, e1009962.	1.5	1
1140	Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy. ACS Applied Materials & Interfaces, 2022, 14, 21836-21847.	4.0	14
1141	SNAT7 regulates mTORC1 via macropinocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123261119.	3.3	9
1142	Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment. Journal of Biomolecular Structure and Dynamics, 2022, , 1-13.	2.0	4
1143	RHOA takes the RHOad less traveled to cancer. Trends in Cancer, 2022, 8, 655-669.	3.8	11
1144	AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nature Communications, 2022, 13, 2572.	5.8	3

#	Article	IF	Citations
1145	Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study. Oncotarget, 2022, 13, 686-693.	0.8	4
1146	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	7.7	38
1147	Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization. International Journal of Molecular Sciences, 2022, 23, 5424.	1.8	16
1148	Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins. Cancers, 2022, 14, 2327.	1.7	8
1149	The Tumor Suppressor Kinase LKB1: Metabolic Nexus. Frontiers in Cell and Developmental Biology, 2022, 10, 881297.	1.8	9
1150	More to the RAS Story: KRAS^{G12C} Inhibition, Resistance Mechanisms, and Moving Beyond KRAS^{G12C}. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 205-217.	1.8	13
1151	Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells. OncoImmunology, 2022, 11, 2069214.	2.1	4
1152	Penipentenone A and brefeldin A derivatives potently inhibit KRAS mutant cancer cells from an endophytic fungus Penicillium brefeldianum F4a. Phytochemistry, 2022, 200, 113243.	1.4	4
1154	T cells discriminate between groups C1 and C2 HLA-C. ELife, 2022, 11, .	2.8	5
1155	Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. BMC Clinical Pathology, 2022, 15, 2632010X2211020.	0.7	2
1158	HSc70 interactome reveal major role of macroautophagy and minor role of chaperone mediated autophagy in K-Ras G12V cell proliferation and survival. Journal of Proteomics, 2022, 264, 104614.	1.2	1
1159	Fasting and cancer: from yeast to mammals. International Review of Cell and Molecular Biology, 2022, , 81-106.	1.6	1
1160	FL118, acting as a â€˜molecular glue degraderâ€™, binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control câ€Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clinical and Translational Medicine, 2022, 12, .	1.7	12
1161	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. IScience, 2022, 25, 104483.	1.9	4
1162	Fluorine-containing drugs approved by the FDA in 2021. Chinese Chemical Letters, 2023, 34, 107578.	4.8	67
1164	Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition. Journal of Biological Chemistry, 2022, 298, 102186.	1.6	5
1166	Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology. Journal of Medicinal Chemistry, 2022, 65, 8961-8974.	2.9	7
1167	Development of PD3 and PD3-B for PDEÎ´ inhibition to modulate KRAS activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1656-1666.	2.5	0

#	Article	IF	Citations
1168	The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinics and Practice, 2022, 12, 419-424.	0.6	4
1169	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Reports, 2022, 39, 110993.	2.9	34
1170	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14
1172	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	3.4	15
1173	4â€²â€Câ€Aminoethoxyâ€Modified DNAs Exhibit Increased Nuclease Resistance, Sustained RNase H Activity, and Inhibition of KRAS Gene Expression. Chemistry and Biodiversity, 2022, 19, .	1.0	0
1174	Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers. International Journal of Molecular Sciences, 2022, 23, 7168.	1.8	4
1175	Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. Cancer Research, 2022, 82, 3002-3015.	0.4	12
1176	Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells, 2022, 11, 2183.	1.8	18
1177	Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study. Journal of Clinical Medicine, 2022, 11, 4098.	1.0	4
1178	Morindone from Morinda citrifolia as a potential antiproliferative agent against colorectal cancer cell lines. PLoS ONE, 2022, 17, e0270970.	1.1	9
1179	Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. ELife, 0, 11, .	2.8	32
1180	Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies, 2022, 11, 47.	1.2	7
1181	Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice. Nature Biotechnology, 2022, 40, 1834-1844.	9.4	13
1183	How can we use the endocytosis pathways to design nanoparticle drug-delivery vehicles to target cancer cells over healthy cells?. Chemical Society Reviews, 2022, 51, 7531-7559.	18.7	27
1184	Argonaute 2 modulates EGFRâ€“RAS signaling to promote mutant HRAS and NRAS-driven malignancies. , 2022, 1, .		1
1185	Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C. Frontiers in Oncology, 0, 12, .	1.3	5
1186	AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Molecular Cancer Therapeutics, 2022, 21, 1535-1546.	1.9	2
1187	Functional and biological heterogeneity of KRAS ^{Q61} mutations. Science Signaling, 2022, 15, .	1.6	12

#	Article	IF	Citations
1188	Synthetic lethality in personalized cancer therapy. Genome Instability & Disease, 0, , .	0.5	0
1189	A Combinatorial Library of Biodegradable Lipid Nanoparticles Preferentially Deliver mRNA into Tumor Cells to Block Mutant RAS Signaling. Advanced Functional Materials, 2022, 32, .	7.8	15
1190	KRAS-targeted therapy in the treatment of non-small cell lung cancer. Journal of Oncology Pharmacy Practice, 2023, 29, 422-430.	0.5	1
1192	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. International Journal of Molecular Sciences, 2022, 23, 9391.	1.8	13
1193	Targeting RNA structures with small molecules. Nature Reviews Drug Discovery, 2022, 21, 736-762.	21.5	153
1194	TGFÎ²-induced changes in membrane curvature influence Ras oncoprotein membrane localization. Scientific Reports, 2022, 12, .	1.6	4
1195	Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies. Cancers, 2022, 14, 3778.	1.7	6
1196	Bourgeoning Cancer Targets. Recent Patents on Anti-Cancer Drug Discovery, 2023, 18, 147-160.	0.8	2
1197	Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Molecular Cancer, 2022, 21, .	7.9	55
1198	Novel natural inhibitors targeting KRAS G12C by computational study. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	0
1199	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers, 2022, 14, 4103.	1.7	14
1200	CDK4: a master regulator of the cell cycle and its role in cancer. Genes and Cancer, 2022, 13, 21-45.	0.6	18
1202	Nanocarriers escaping from hyperacidified endo/lysosomes in cancer cells allow tumor-targeted intracellular delivery of antibodies to therapeutically inhibit c-MYC. Biomaterials, 2022, 288, 121748.	5.7	16
1203	The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology, 2022, 19, 637-655.	12.5	125
1204	Synthesis, biological evaluation, and bindingâ€mode of a new class of oncogenic Kâ€Ras4B inhibitors. ChemMedChem, 0, , .	1.6	2
1205	Mechanistic Insights into the Long-range Allosteric Regulation of KRAS Via Neurofibromatosis Type 1 (NF1) Scaffold Upon SPRED1 Loading. Journal of Molecular Biology, 2022, 434, 167730.	2.0	17
1206	Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. Bioorganic and Medicinal Chemistry, 2022, 71, 116962.	1.4	6
1207	Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity. Bioorganic and Medicinal Chemistry, 2022, 71, 116949.	1.4	6

#	Article	IF	Citations
1208	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Seminars in Cancer Biology, 2022, 86, 14-27.	4.3	21
1209	Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 30, 49-61.	2.3	6
1210	KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. Journal of Cancer, 2022, 13, 3209-3220.	1.2	10
1211	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	13
1212	SFPQ promotes RAS-mutant cancer cell growth by modulating 5â€²-UTR mediated translational control of CK1Î±. NAR Cancer, 2022, 4, .	1.6	1
1213	The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth. Cell Reports, 2022, 40, 111267.	2.9	3
1215	RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma. Nature Communications, 2022, 13, .	5.8	17
1216	<scp>KRAS</scp> mutated Nonâ€Small Lung Carcinoma: A Real World Context from the Indian subcontinent. Cancer Medicine, 0, , .	1.3	0
1217	Case report: Common clonal origin of concurrent langerhans cell histiocytosis and acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	3
1219	KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement. ACS Bio & Med Chem Au, 2022, 2, 617-626.	1.7	4
1220	Assessing Oncologistsâ€™ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data. JNCI Cancer Spectrum, 0, , .	1.4	2
1221	Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?. Pediatric Blood and Cancer, 2022, 69, .	0.8	2
1222	Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis. Cancer Research, 2022, 82, 4153-4163.	0.4	6
1224	Hydrophobic Tag Tethering Degradation, The Emerging Targeted Protein Degradation Strategy. Current Medicinal Chemistry, 2023, 30, 3137-3155.	1.2	2
1225	Targeting K-Ras Mutations Show Promise Towards Ending Rasâ€™s â€œUndruggableâ€•Era. Protein and Peptide Letters, 2022, 29, 1007-1015.	0.4	0
1227	Liquid-liquid phase separation: A new perspective to understanding aging and pathogenesis. BioScience Trends, 2022, 16, 359-362.	1.1	3
1228	Management of Locally Advanced/Metastatic Disease: Medical Oncology. , 2022, , 97-106.		0
1229	An evaluation of sotorasib for the treatment of patients with nonâ€“small cell lung cancer with KRASG12C mutations. Expert Opinion on Pharmacotherapy, 2022, 23, 1569-1575.	0.9	1

#	Article	IF	Citations
1230	Inhibition of colon cancer K-RasG13D mutation reduces cancer cell proliferation but promotes stemness and inflammation via RAS/ERK pathway. Frontiers in Pharmacology, 0, 13, .	1.6	5
1231	Targeting KRAS in PDAC: A New Way to Cure It?. Cancers, 2022, 14, 4982.	1.7	15
1233	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	1.7	11
1234	Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRASâ€‘mutated lung cancer cells. Oncology Reports, 2022, 48, .	1.2	10
1235	Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Scientific Reports, 2022, 12, .	1.6	24
1236	Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer. Molecular Cancer Therapeutics, 2023, 22, 135-149.	1.9	2
1237	The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Molecular Cancer Therapeutics, 2022, 21, 1645-1651.	1.9	6
1238	Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells. Cells, 2022, 11, 3273.	1.8	4
1239	Selective Metalation of Functionalized Quinazolines to Enable Discovery and Advancement of Covalent KRAS Inhibitors. Organic Process Research and Development, 2022, 26, 2926-2936.	1.3	2
1240	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications, 2023, 43, 42-74.	3.7	9
1241	K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. Cancers, 2022, 14, 5322.	1.7	1
1242	The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer. Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÃ¢, VraÄ•I ZdorovÊ¹e, 0, , .	0.1	0
1243	Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations. Molecular Diversity, 2023, 27, 1795-1807.	2.1	3
1244	Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting Î²-catenin and Ras degradation. Bioorganic Chemistry, 2023, 130, 106234.	2.0	0
1245	Enhancing an Oxidative â€œTrojan Horseâ€•Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside. Cells, 2022, 11, 3454.	1.8	2
1246	RAS: Circuitry and therapeutic targeting. Cellular Signalling, 2023, 101, 110505.	1.7	1
1247	NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. International Journal of Molecular Sciences, 2022, 23, 14054.	1.8	1
1248	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences, 2022, 23, 13696.	1.8	0

#	Article	IF	Citations
1249	Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Current Treatment Options in Oncology, 2022, 23, 1699-1720.	1.3	5
1250	Role of RAS signaling in ovarian cancer. F1000Research, 0, 11, 1253.	0.8	8
1251	The molecular genetics of <scp>RASopathies</scp>: An update on novel disease genes and new disorders. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 425-439.	0.7	11
1252	In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis. International Journal of Molecular Sciences, 2022, 23, 13845.	1.8	7
1253	RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases. Annals of Surgical Oncology, 0, , .	0.7	2
1254	HRAS. Encyclopedia of Pathology, 2022, , 371-373.	0.0	0
1255	Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188848.	3.3	3
1256	Validation of an LCâ€“MS/MS method for the determination of sotorasib, a KRAS^{G12C} inhibitor, in human plasma. Bioanalysis, 2022, 14, 1281-1292.	0.6	5
1257	Novel 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione derivatives for treating cancer and other disorders associated with KRAS activity. Anti-Cancer Agents in Medicinal Chemistry, 2022, 23, .	0.9	0
1258	Silencing effects of mutant RAS signalling on transcriptomes. Advances in Biological Regulation, 2022, , 100936.	1.4	0
1259	Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. Frontiers in Oncology, 0, 12, .	1.3	7
1260	Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. Journal of Clinical Investigation, 2023, 133, .	3.9	16
1261	Targeting PI3KÎ± overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R. Acta Pharmacologica Sinica, 2023, 44, 1083-1094.	2.8	4
1262	Glimmers of hope for targeting oncogenic KRAS-G12D. Cancer Gene Therapy, 0, , .	2.2	1
1263	Green Chemistry Method Based on Native Fluorescence for Estimation of Recently Approved Anti-neoplastic Drug Sotorasib. Analytical Chemistry Letters, 2022, 12, 761-769.	0.4	0
1264	Middle East and North Africa Registry to Characterize Rate of RAS Testing Status in Newly Diagnosed Patients with Metastatic Colorectal Cancer. Turkish Journal of Gastroenterology, 2023, 34, 118-127.	0.4	0
1265	Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. ELife, 0, 11, .	2.8	4
1266	Comprehensive Analysis of the Expression and Clinical Significance of RAS Family Members in Non-Small Cell Lung Cancer Based on Bioinformatics Data and the A549 Cell Line Model. Applied Sciences (Switzerland), 2023, 13, 166.	1.3	0

#	Article	IF	Citations
1268	PPDPF Promotes the Development of Mutant KRASâ€Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1. Advanced Science, 0, , 2202448.	5.6	1
1270	Protein Phase Separation: New Insights into Carcinogenesis. Cancers, 2022, 14, 5971.	1.7	0
1271	Low dose radiation upregulates Ras/p38 and NADPH oxidase in mouse colon two months after exposure. Molecular Biology Reports, 2023, 50, 2067-2076.	1.0	1
1272	Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation. Frontiers in Pharmacology, 0, 13, .	1.6	3
1273	The function of miR-145 in colorectal cancer progression; an updated review on related signaling pathways. Pathology Research and Practice, 2023, 242, 154290.	1.0	2
1275	From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Frontiers in Medicine, 0, 9, .	1.2	2
1277	Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection. Frontiers in Oncology, 0, 12, .	1.3	2
1279	Design, synthesis and biological evaluation of KRASG12C-PROTACs. Bioorganic and Medicinal Chemistry, 2023, 78, 117153.	1.4	7
1280	Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Development Research, 2023, 84, 337-394.	1.4	6
1281	Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth. Nature Cell Biology, 2023, 25, 159-169.	4.6	9
1282	RAS nanoclusters are cell surface transducers that convert extracellular stimuli to intracellular signalling. FEBS Letters, 2023, 597, 892-908.	1.3	8
1283	Constant p.L424H Mutation in GTF2I in Micronodular Thymomas With Lymphoid Stroma: Evidence Supporting Close Relationship With Type A and AB Thymomas. Modern Pathology, 2023, 36, 100008.	2.9	2
1284	Annual review of KRAS inhibitors in 2022. European Journal of Medicinal Chemistry, 2023, 249, 115124.	2.6	15
1285	RASON, a new player in cancerâ€™s Premier League. Cell Research, 2023, 33, 1-2.	5.7	0
1286	Î±4-Î±5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death. International Journal of Molecular Sciences, 2023, 24, 748.	1.8	2
1287	Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer. Cancers, 2023, 15, 303.	1.7	2
1288	Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?. European Journal of Medicinal Chemistry, 2023, 248, 115104.	2.6	3
1289	Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. ESMO Open, 2023, 8, 100748.	2.0	0

#	Article	IF	Citations
1290	Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study. International Journal of Molecular Sciences, 2023, 24, 669.	1.8	6
1291	Targeting KRAS G12C mutations in colorectal cancer. Gastroenterology Report, 2022, 11, .	0.6	1
1292	Hindered Biaryl Bond Construction and Subsequent Diastereomeric Crystallization to Produce an Atropisomeric Covalent KRAS^{G12C} Inhibitor ARS-2102. Organic Process Research and Development, 2023, 27, 206-216.	1.3	3
1293	Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. IScience, 2023, 26, 106082.	1.9	2
1294	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. Npj Genomic Medicine, 2023, 8, .	1.7	15
1295	Discovering potential stabilizers for KRAS22RT G-quadruplex DNA: an alternative next generation approach to treat pancreatic cancer. Journal of Biomolecular Structure and Dynamics, 2023, 41, 11957-11968.	2.0	0
1296	Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110Î±. Scientific Reports, 2023, 13, .	1.6	0
1297	First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation. Current Medicinal Chemistry, 2024, 31, 266-272.	1.2	2
1298	Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer. Scientific Reports, 2023, 13, .	1.6	9
1299	Targeting Rat Sarcoma Viral Oncogene Homolog for Treatment of Gastrointestinal Cancers. Advances in Oncology, 2023, 3, 161-177.	0.1	0
1300	Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors. Drug Discovery Today, 2023, 28, 103557.	3.2	10
1301	Nanobody Loop Mimetics Enhance Son of Sevenless 1â€Catalyzed Nucleotide Exchange on RAS**. Angewandte Chemie - International Edition, 2023, 62, .	7.2	1
1302	Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 7310.	1.8	4
1303	Prediction of KRASG12C inhibitors using conjoint fingerprint and machine learning-based QSAR models. Journal of Molecular Graphics and Modelling, 2023, 122, 108466.	1.3	3
1304	Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer. Oncologie, 2022, 24, 613-648.	0.2	8
1305	The impact of RAS mutation on the treatment strategy of colorectal cancer. Medicine and Pharmacy Reports, 2023, 96, 5-15.	0.2	0
1306	An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1765-1779.	3.3	4
1307	143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models. Acta Pharmacologica Sinica, 0, , .	2.8	0

#	Article	IF	Citations
1309	Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors. Molecular Cancer Therapeutics, 2023, 22, 529-538.	1.9	1
1310	Analysis of KRASâ€“Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics. Journal of Chemical Information and Modeling, 2023, 63, 1362-1370.	2.5	2
1311	Targeting the â€˜Undruggableâ€™ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective. Cells, 2023, 12, 631.	1.8	8
1312	Environmentally sensitive fluorescent probes with improved properties for detecting and imaging PDEÎ´ in live cells and tumor slices. Chinese Chemical Letters, 2023, 34, 108231.	4.8	1
1313	Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers. ACS Applied Materials & Interfaces, 2023, 15, 10398-10413.	4.0	3
1314	Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical developmentâ€”a narrative review. Translational Lung Cancer Research, 2023, 12, 346-368.	1.3	5
1316	KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions. Cells, 2023, 12, 749.	1.8	5
1317	Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. Current Issues in Molecular Biology, 2023, 45, 1914-1949.	1.0	2
1318	KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study. Lung Cancer, 2023, 178, 172-182.	0.9	1
1319	Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents. RSC Advances, 2023, 13, 6872-6908.	1.7	9
1320	Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutantâ€”Novel Insights from Computer-Aided Drug Discovery. Current Issues in Molecular Biology, 2023, 45, 2136-2156.	1.0	5
1321	Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry. Analytical Chemistry, 2023, 95, 4834-4839.	3.2	1
1322	Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis. Open Medicine (Poland), 2023, 18, .	0.6	1
1323	Realâ€world retrospective study of KRAS mutations in advanced nonâ€“small cell lung cancer in the era of immunotherapy. Cancer, 2023, 129, 1662-1671.	2.0	2
1324	Emerging roles of i-motif in gene expression and disease treatment. Frontiers in Pharmacology, 0, 14, .	1.6	4
1325	DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer Research, 2023, 83, 1800-1814.	0.4	1
1327	Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma. Journal of Medicinal Chemistry, 2023, 66, 5171-5184.	2.9	5
1328	Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines. Oncotarget, 2023, 14, 243-257.	0.8	1

#	Article	IF	Citations
1329	Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations. Molecules, 2023, 28, 2886.	1.7	2
1330	Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. ELife, 0, 12, .	2.8	0
1331	KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane. Frontiers in Oncology, 0, 13, .	1.3	1
1332	Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling. Journal of Medicinal Chemistry, 2023, 66, 4324-4341.	2.9	9
1333	PROTACâ€™ing oncoproteins: targeted protein degradation for cancer therapy. Molecular Cancer, 2023, 22, .	7.9	18
1334	RASgene mutations and histomorphometric measurements in oral squamous cell carcinoma. Biotechnic and Histochemistry, 2023, 98, 382-390.	0.7	0
1336	Precision Medicine in Pancreatitis: The Future of Acute Pancreatitis Care. Function, 2023, 4, .	1.1	2
1337	KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics. Recent Patents on Anti-Cancer Drug Discovery, 2024, 19, 268-279.	0.8	1
1338	Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs. Chemical Papers, 2023, 77, 4085-4106.	1.0	13
1339	Smallâ€Molecule Modulation of Protein Lipidation: From Chemical Probes to Therapeutics. ChemBioChem, 2023, 24, .	1.3	1
1340	Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2023, 36, 415-422.	0.5	1
1341	Nanobody Loop Mimetics Enhance Son of Sevenless 1â€Catalyzed Nucleotide Exchange on RAS**. Angewandte Chemie, 2023, 135, .	1.6	0
1343	MicroRNA-708 emerges as a potential candidate to target undruggable NRAS. PLoS ONE, 2023, 18, e0284744.	1.1	0
1344	The Emerging Role of Molecular Dynamics Simulations in Cancer Research. , 2024, , 910-920.		0
1356	Advances in KRAS mutation inhibition in metastatic colorectal cancer. , 2023, 2, .		0
1374	Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
1375	Diagnostic applications and therapeutic option of Cascade CRISPR/Cas in the modulation of miRNA in diverse cancers: promises and obstacles. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9557-9575.	1.2	2
1391	Small-Molecule Inhibitors of Proteinâ€“Protein Interactions as Therapeutics. , 2023, , 343-428.		0

#	Article	IF	Citations
1393	Adenosquamous carcinoma of the gallbladder simultaneously producing granulocyte-colony-stimulating factor and parathyroid hormone-related protein. Clinical Journal of Gastroenterology, 2023, 16, 901-907.	0.4	2
1395	Recent advances in targeting the â€œundruggableâ€•proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	11
1429	Insights into the structure and function of the RNA ligase RtcB. Cellular and Molecular Life Sciences, 2023, 80, .	2.4	1
1450	Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors. International Review of Cell and Molecular Biology, 2024, , 1-39.	1.6	0
1453	Targeting KRAS G12C: progress made and promise ahead. , 2024, , .		0
1458	Precision medicine: success stories and challenges from science to implementation. , 2024, , 83-113.		0